Imaging of the brain opioid system in amphetamine dependence by Guterstam, Joar
From THE DEPARTMENT OF CLINICAL NEUROSCIENCE 
Karolinska Institutet, Stockholm, Sweden 
IMAGING OF THE BRAIN OPIOID SYSTEM 
IN AMPHETAMINE DEPENDENCE 
Joar Guterstam 
 
Stockholm 2017 
 
 Front cover: 11C-carfentanil PET images, coronal slices at the level of the striatum. 
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print AB 
© Joar Guterstam, 2017 
ISBN 978-91-7676-861-7 
Imaging of the brain opioid system in amphetamine 
dependence 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
Public defense in Petrénsalen, Nobels väg 12 B, Karolinska Institutet 
Tuesday the 21st of November, 2017 at 09:00 
 
By 
Joar Guterstam 
Principal Supervisor: 
Professor Johan Franck 
Karolinska Institutet 
Department of clinical neuroscience 
Division of psychiatry 
 
Co-supervisor: 
Assistant professor Nitya Jayaram-Lindström 
Karolinska Institutet 
Department of clinical neuroscience 
Division of psychiatry 
Opponent: 
Professor Trevor Robbins 
University of Cambridge 
Department of psychology 
 
Examination Board: 
Professor Sophie Erhardt 
Karolinska Institutet 
Department of physiology and pharmacology 
Division of pharmacology 
 
Associate professor Johan Lundberg 
Karolinska Institutet 
Department of clinical neuroscience 
Division of psychiatry 
 
Professor Markus Heilig 
Linköping University 
Department of clinical and experimental medicine 
Centre for social and affective neuroscience 
 
 

  
 
 
 
 
 
 
 
Nichts ist unergründlicher, als das System von Triebfedern unserer Handlungen. 
G.C. Lichtenberg 
  
  
  
ABSTRACT 
Amphetamine dependence is a global health problem, often giving rise to severe medical and 
social complications in affected individuals. Unfortunately, there is still limited evidence for 
any specific treatment that would help amphetamine dependent patients to avoid relapse. One 
of the most promising treatments is the opioid antagonist naltrexone, which has been shown 
to attenuate the subjective effects of amphetamine and in some randomized clinical trials also 
reduce the risk of relapse. The aim of this thesis work was to investigate the mechanism of 
action of naltrexone for amphetamine dependence, in order to better understand the 
neurobiology involved and facilitate further treatment development. We used the 
neuroimaging techniques positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) to study these processes in the human brain. 
In Study I, we tested the hypothesis that an amphetamine injection causes a release of 
endogenous opioids in the brain, which might explain why an opioid antagonist such as 
naltrexone attenuates the subjective effects of amphetamine. However, using PET and the µ 
opioid radioligand 11C-carfentanil, we found no evidence of such an amphetamine-induced 
opioid release in healthy human subjects without any previous experience of amphetamine. 
Study II investigated whether naltrexone pre-treatment affects the dopamine release that 
occurs in the brain after amphetamine intake, an effect that some previous studies have found 
to correlate with the subjective effects of amphetamine. If naltrexone were to attenuate this 
dopamine release, it might help to explain why it affects the subjective effects of 
amphetamine. In a first experiment, we used PET and the radioligand 11C-raclopride, but 
found no evidence that naltrexone affected amphetamine-induced dopamine release in 
healthy, previously amphetamine-naïve human subjects. We proceeded with experiments 
using in vivo microdialysis in rats, where similar results were found: pre-treatment with 
naltrexone did not affect the dopamine release caused by an acute amphetamine dose in rats 
without previous exposure to amphetamine. However, in rats that had been treated with 
amphetamine for a longer time period, naltrexone did attenuate the dopamine release when 
amphetamine was reinstated, suggesting that the brain opioid system might be involved in the 
adaptations to chronic amphetamine exposure.  
In Study III, we investigated the effects of naltrexone on cue reactivity, i.e. the reaction of 
substance dependent patients to environmental stimuli reminding them of drug use. This 
process is interesting as it can be an important trigger of relapse. For this study, we included 
40 men with severe, intravenous amphetamine dependence, who received one oral dose of 
naltrexone or placebo and then underwent an fMRI examination including exposure to drug-
related and neutral film clips. The hypothesis was that the drug-related films would cause a 
subjective craving reaction and increase the activity of a number of motivationally relevant 
brain regions, and that naltrexone would attenuate this reactivity. We found that the films did 
cause strong craving and wide-spread fMRI activations, but there was no evidence of any 
effect of naltrexone on these measures. 
Study IV investigated the proposed phenomenon of subliminal cue reactivity, where the 
brains of substance dependent patients have been reported to react specifically to drug-related 
pictures, even when the pictures are presented very fast and with a backward mask, so that 
they never reach conscious awareness. In our study, which used the same patient sample as 
Study III and 30 healthy controls, we found no evidence of any subliminal drug cue 
reactivity. Upon closer examination of the earlier studies, we found that the reliability of their 
statistical inferences could be questioned, which together with our negative results suggest 
that there is no strong evidence for subliminal cue reactivity in addiction. 
In summary, the studies of this thesis have not corroborated the hypotheses we started out 
with regarding the mechanisms behind naltrexone’s effects in amphetamine dependence. 
Instead, the results have inspired new hypotheses, for example regarding how the interplay 
between the brain dopamine and opioid systems may change with long-term amphetamine 
use. These studies have also highlighted methodological challenges that may help to improve 
future neuroimaging studies of addiction.  
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1 INTRODUCTION 
This thesis is based on four studies, which will be discussed alongside each other throughout 
the text. First, we will look at the background to the research project as a whole, including the 
diagnosis, epidemiology and pathophysiology of amphetamine dependence. Special attention 
is paid to previous research on the pathophysiologic role of the opioid system and the use of 
the opioid antagonist naltrexone as a treatment for amphetamine dependence. I will also 
introduce the main neuroimaging approaches currently used in the study of substance use 
disorders. 
The third chapter articulates the scientific aims of the thesis. Chapter four describes the 
methods used in the four studies, in particular the study designs and imaging technologies 
employed. After that, the main findings of each study are described in chapter five.  
In the sixth chapter, the results are discussed in relation to the current state of the research 
field. Specifically, I will discuss the role of the opioid system in two different parts of the so-
called cycle of addiction: the acute effects of amphetamine intake and the longer-term 
consequences of craving and relapse. 
The discussion is summed up in a chapter with conclusions and future perspectives, followed 
by acknowledgements and references. The four individual manuscripts on which the thesis is 
based are provided as attachments. 
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2 BACKGROUND 
2.1 AMPHETAMINE DEPENDENCE: HISTORY, EPIDEMIOLOGY AND 
CLINICAL PICTURE 
Amphetamine was first synthesized in Berlin in the end of the 19th century, but was never put 
to any medical use until it was rediscovered by Gordon Alles in the United States in 1927 (1). 
In the 1930s and 40s, amphetamine became one of the best selling drugs in the world, 
marketed for the treatment of asthma, obesity and depression but also used for conditions like 
headache, alcoholism and general fatigue (2,3). Especially during the Second World War, 
amphetamine and the closely related compound methamphetamine were widely used as 
powerful stimulants that enabled soldiers to stay awake for long periods of time. 
After the war, when amphetamine use became even more widespread in the general 
population, the adverse consequences of the drug became apparent. In particular, the risk of 
addiction to amphetamines was recognized. During the 1950s and 60s, the role of 
amphetamine changed from being a legitimate pharmaceutical product to becoming one of 
the dominating “recreational” drugs of the emerging youth culture. From over-the-counter 
sales it became strictly regulated and eventually banned internationally by the United Nations 
in the 1970s (4).  
In Sweden and the other Nordic countries, amphetamine came to be the dominating drug 
among injecting drug users, a pattern that is still apparent today. The latest major survey of 
illegal drug use in Sweden was conducted in 1998 and concluded that approximately 26 000 
people were “heavy drug users” and 73% of them used amphetamine regularly, although 
many of them also used cannabis or other drugs (5). Several minor surveys have been 
conducted since then and most indicators suggest that there has been a rise in the number of 
heavy drug users during the recent years. For instance, the amount of amphetamine seized by 
Swedish police and customs has been increasing steadily for decades; however, such 
indicators can be hard to interpret since they are affected by changes in laws, resources and 
priorities in the involved authorities (6). 
In the 2017 “World Drug Report” from the United Nations Office on Drugs and Crime, the 
number of people that have used amphetamine in the last year is estimated to 35 million, 
equivalent to a global prevalence of 0.8% in the population aged 15-64 (7). However, many 
of these users do not suffer from amphetamine dependence: although the “World Drug 
Report” offers no specific estimate, earlier epidemiological surveys in the United States have 
found that about 20% of stimulant users eventually go on to develop addiction (8,9). This 
proportion is likely to exhibit significant regional variation, depending on a number of 
different factors such as the socio-cultural context of the drug use and the typical route of 
administration, which is intravenous in the Nordic countries as opposed to oral in many other 
parts of the world. 
Long-term use of amphetamine may cause a number of medical problems. Because of its 
vasoconstrictive and sympathomimetic properties, with strong elevations of heart rate and 
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blood pressure, amphetamine use increases the risk of cardiovascular disease and death (10). 
Amphetamine may cause xerostomia and bruxism, which along with poor oral hygiene 
contributes to the high prevalence of dental problems among amphetamine users (11). If the 
drug is injected, there is an increased risk of infections such as endocarditis, HIV and viral 
hepatitis; indeed, a majority of injection drug users in Sweden are infected with hepatitis C 
virus and users of amphetamine show particularly high levels of injection risk behavior 
(12,13). Amphetamine users often exhibit neurological symptoms such as choreiform 
movements and ataxia, and in some cases these symptoms remain even after many years of 
abstinence (14). A number of less common medical complications, such as rhabdomyolysis, 
hepatotoxicity and seizures, have also been described in the literature (15). The severe social 
problems associated with amphetamine use often complicate the management of these 
medical conditions. 
Within psychiatry, the most dramatic complication is amphetamine-induced psychosis, an 
acute psychotic state often characterized by delusions of persecution, hallucinations and 
agitation (16). Typically, amphetamine-induced psychotic symptoms remit within a couple of 
days of abstinence. Whether such episodes increase the risk of chronic psychotic syndromes 
such as schizophrenia is unclear, although a recent register study from Finland found that as 
much as 30% of the patients diagnosed with amphetamine-induced psychosis received the 
diagnosis of schizophrenia within eight years of follow-up (17). Interestingly, psychotic 
reactions to methamphetamine have been described in the Japanese medical literature for 
decades, and in these studies about 10-30% of the patients continue to experience psychotic 
symptoms even after more than one month of abstinence (18). Importantly, neither the 
Finnish nor the Japanese studies on this topic have taken genetic and other possible 
confounders into account, and it is possible that some of these patients would have developed 
long-term psychotic syndromes even if they had never used amphetamine. 
In contrast to the dramatic symptoms that might be seen after amphetamine intake and 
intoxication, the amphetamine withdrawal syndrome is typically not very severe, with mild to 
moderate dysphoria and excessive sleep for a couple of days after a longer period of 
amphetamine intake. 
A common psychiatric co-morbidity that has gained a lot of attention in recent years is 
attention-deficit hyperactivity disorder (ADHD). By definition, ADHD is a 
neurodevelopmental disorder that is present from childhood and therefore cannot be 
considered a complication of amphetamine use, which typically starts in teenagers or young 
adults (19). ADHD is a strong risk factor for substance use disorders and the prevalence rate 
among patients seeking treatment for addiction is estimated to be 20-25% (20). It has long 
been known that ADHD can be symptomatically treated with stimulants, and recent studies 
have shown that this can be the case even in many patients with stimulant use disorders if the 
dose is high enough (21,22). Of course, the risks of medication diversion and misuse also 
have to be taken into account when prescribing stimulants. 
As mentioned above, amphetamine addiction was recognized as a growing problem in the 
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1960s and “stimulant dependence” (with amphetamine as the prototypical substance) was 
included as a disorder in the American Psychiatric Associations Diagnostic and Statistical 
Manual for Mental Disorders-III (DSM-III) in 1980, applying the same criteria as for other 
substance dependence syndromes (e.g. alcohol and opioid dependence) (23). The revised 
manual DSM-III-R of 1987 made a distinction between the compulsive drug use of substance 
dependence and the supposedly less severe condition of substance abuse, a residual category 
for patients that did not meet criteria for dependence but still exhibited social complications 
and risky drug intake. This distinction was preserved in the DSM-IV but abandoned in the 
DSM-5, the currently used version that was released in 2013 (19). The so-called stimulant use 
disorder of DSM-5 combines the earlier diagnostic criteria for both stimulant dependence and 
abuse, with the exception of the removal of a legal complications criterion and the addition of 
craving as a new criterion. The following, abbreviated DSM-5 list of diagnostic criteria for 
stimulant use disorder also gives an idea of the problems amphetamine dependent patients 
may present with: 
1. The stimulant is often taken in larger amounts or over a longer period than was 
intended. 
2. Persistent desire or unsuccessful efforts to cut down. 
3. A great deal of time is spent in order to obtain, use and recover from use of the 
stimulant. 
4. Craving, or a strong desire or urge to use the stimulant. 
5. Recurrent stimulant use resulting in a failure to fulfill major role obligations at work, 
school, or home. 
6. Continued use despite persistent or recurrent social problems caused or exacerbated 
by the use. 
7. Important activities are given up or reduced because of stimulant use. 
8. Recurrent stimulant use in situations in which it is physically hazardous. 
9. Stimulant use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated 
by the stimulant. 
10. Tolerance, i.e. a need for markedly increased amounts of the stimulant to achieve the 
desired effect. 
11. Withdrawal. 
A new feature of DSM-5 is the grading of severity based on the number of diagnostic criteria 
fulfilled, such that mild = presence of 2-3 symptoms, moderate = 4-5 symptoms, and severe = 
6 or more symptoms. 
In parallel to the DSM, the World Health Organization has its own International 
Classification of Diseases (ICD), currently in its tenth edition (24). Their categorization of 
substance use disorders is quite similar to the DSM-IV, with two diagnostic categories 
(‘dependence’ and ‘harmful use’) for each drug. Notably, the ICD-10 lists craving as a 
symptom of substance dependence, which was not included in the DSM before its current, 
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fifth edition. At present, it is still unclear how ICD-11, due to be released in 2018, will 
classify these disorders. 
The patients included in Study III of this thesis were all diagnosed with amphetamine 
dependence according to DSM-IV. Since we only recruited patients with long histories of 
intravenous amphetamine use, they would all qualify for a diagnosis of severe amphetamine 
use disorder according to DSM-5. In this thesis, the terms amphetamine dependence and 
addiction will be used as synonyms, along with the somewhat wider DSM-5 category of 
amphetamine use disorder. 
2.2 PATHOPHYSIOLOGY OF AMPHETAMINE DEPENDENCE 
Amphetamine is often considered the prototypical stimulant drug because of its strongly 
activating physiological and psychological effects. It typically reduces the urge to sleep and 
eat food and causes sympathomimetic effects such as mydriasis and heightening of heart rate 
and blood pressure. Amphetamine may also cause a strong euphoria, in particular when it is 
administered intravenously, as is common among Swedish users (25–27). 
Early research on the brain monoamine systems revealed that amphetamine stimulated 
dopamine (DA) release (28). These effects, particularly the strong elevation of extracellular 
DA levels in the ventral striatum, were quantified in rats using in vivo microdialysis in the 
1980s (29) and in humans using 11C-raclopride positron emission tomography (PET) in the 
1990s (30,31). The magnitude of amphetamine-induced mesolimbic DA release can be 
several times higher than that produced by “natural” rewards such as sex (32). While some 
early studies found a correlation between DA release and subjective euphoria (25), other 
studies have indicated a relationship to drug wanting rather than euphoria or liking (33,34). 
A number of case-control PET studies, particularly from the laboratory of Nora Volkow, 
have found that amphetamine dependent patients, as compared to healthy controls, have low 
densities of striatal DA D2 receptors and blunted DA responses to stimulants (35–37)(Figure 
1). In some studies, such abnormalities in the DA system have been associated with increased 
risk of relapse, although the studies are small and the conclusions therefore highly tentative 
(36). There is some evidence for the involvement of DA in stimulant craving reactions: in 
two PET studies with cocaine dependent patients, drug cues activated mesolimbic and 
mesocortical DA systems (38,39). 
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Figure 1. Meta-analysis of molecular imaging studies with abstinent amphetamine or methamphetamine users, 
showing decreased dopamine receptor availability in the striatum, as compared with healthy controls. Adapted from 
Ashok et al. JAMA Psychiatry 2017 
There is also a huge body of preclinical research on the role of DA in reward and the 
formation of habits. An influential theory developed by Kent Berridge is that DA encodes 
“incentive salience”: in other words, that DA release is not necessary for us to like a 
particular stimulus, but is essential for causing us to want that stimulus again (40). Of course, 
we often want what we like and vice versa, and these two components of reward might be 
hard to differentiate clinically, although they may be quite distinct at the neurochemical level. 
Based on these findings, the DA system has been the primary focus of many neurobiological 
theories of amphetamine addiction, and indeed of addictive disorders in general, although the 
evidence is weaker for the involvement of DA in for instance opioid or cannabis use disorders 
(41). Disappointingly, no primarily dopaminergic medications have been found effective for 
the treatment of substance use disorders. This could be related to the fact that medications 
that raise DA levels may themselves be addictive or trigger relapse, while DA receptor 
antagonists such as antipsychotic medications often have severe side effects and worsen the 
low DA activity seen in at least some categories of substance users (42). Theoretically, DA 
partial agonists or stabilizers could avoid these problems and be more therapeutically useful, 
but further clinical studies of such compounds are needed (43). 
However, the mesolimbic DA system is not the single mediator of amphetamines effects. 
Surprisingly, repeated laboratory studies have shown that pretreatment with DA D2 
antagonists, even in high doses that effectively block most striatal DA receptors, does not 
attenuate the subjective effects of amphetamine, such as drug liking and wanting more of the 
drug (44,45). This suggests that amphetamine also affects other brain signaling systems, and 
one of these is the endogenous opioid system. 
2.3 THE BRAIN OPIOID SYSTEM 
The brain opioid system comprises four different types of G-protein coupled receptors: µ, δ, 
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κ, and the more recently discovered NOP receptor. Corresponding to these are four different 
genes coding for propeptides that are processed into endogenous opioid ligands with agonist 
properties at their receptor: proopiomelanocortin (β-endorphine), proenkephalin (met-
enkephalin, leu-enkephalin), prodynorphin (dynorphin), and prepronociceptin (nociceptin). 
These ligands are not completely selective, but have differential affinities for each receptor 
type (46). Opioid receptors are inhibitory, attenuating the excitability of the neuron when 
activated. 
The µ receptor was the first opioid receptor to be characterized in the early 1970s and was 
named after its first known ligand, morphine (47–49). It has received great scientific attention 
because of its importance in pain regulation and addiction, and µ receptor agonists such as 
morphine are very useful in health care as powerful analgetics (50). While there is only one 
known gene coding for the µ receptor, there are several versions of the receptor since 
alternative splicing gives rise to different intracellular C terminals, which impacts the second 
messenger effects of receptor activation. The distribution of different splicing variants of the 
µ receptor might therefore be one explanation for individual variability in the 
pharmacological response to opioids (51). A single nucleotide polymorphism (rs1799971, 
A118G) in the first exon of the µ opioid receptor gene is also a source of functional variation, 
since it strongly increases the affinity of β-endorphine to the receptor (52). Interestingly, this 
genetic variant has also been associated with better therapeutic outcomes when treating 
alcohol dependence with the opioid antagonist naltrexone (53). 
µ opioid receptors can be found in the intestines, in peripheral nerves and in all parts of the 
central nervous system (except the occipital lobes of the brain), with a particularly high 
density in the striatum, thalamus, and brain stem. 
The brain opioid system is phylogenetically old, probably dating back around 450 million 
years, and has been evolutionary well preserved so that the same types of opioid receptors 
and ligands can be found in all vertebrates (54). This indicates that the system has an 
important fitness value. It also means that it is possible for experiments involving the opioid 
system in rodents to have translational validity, although there are several challenges in 
translating such research, especially on the behavioral level, to the human condition (55). 
A number of scientific methods have been used to investigate the brain opioid system, 
particularly in animal models. A radical method is to use knockout animals (most often 
mice), where a particular gene has been inactivated and the resulting physiological effects are 
studied. In µ opioid receptor knockout mice, self-administration of opioids is blocked and 
several addictive behaviors are attenuated also for other substances such as alcohol and 
nicotine (56). However, only few studies have looked at the responses of these animals to 
stimulant drugs, and the results are inconclusive (56). A problem with knockout studies is 
that an animal born without a particular gene might compensate for this by some other 
mechanism, thereby clouding the physiological role of the gene in a normal animal. 
Another way to study neurotransmitter systems is microdialysis, an invasive technique where 
a probe with a semipermeable membrane is inserted into the tissue of interest. The probe is 
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perfused with a fluid, allowing for molecules to pass over the membrane by diffusion and the 
contents of the resulting dialysate can then be analyzed. This technique may be used to 
measure the concentration of neurotransmitters, such as endogenous opioids, in rodents in 
vivo. One problem is that the dialysis probe needs to be carefully inserted into a specific 
anatomical spot in the brain, which entails a risk of misplacement and also means that 
neurotransmitter changes in the rest of the brain are not measured. The temporal resolution is 
also somewhat limited, since there needs to be a time interval between every analytic 
sampling, but microdialysis is still a very valuable tool when evaluating for instance 
neurotransmitter release in a specific region in response to different stimuli. In Study II of this 
thesis, microdialysis is used to analyze amphetamine-induced DA release in the nucleus 
accumbens after pre-treatment with naltrexone or vehicle. 
So far, the technique that allows for the most direct study of the opioid system in living 
humans is PET with specific radioligands (see also section 2.6). 
2.4 THE ROLE OF THE OPIOID SYSTEM IN AMPHETAMINE DEPENDENCE 
Since the opioid system has long been known to be involved in addictive behaviors, a number 
of studies have investigated its possible role in the pathophysiology of amphetamine 
dependence. 
One study using microdialysis in rats found that amphetamine injections gave rise to β-
endorphine release in the nucleus accumbens (57). The aim of Study I of this thesis was to 
investigate if that finding could be translated to humans. 
Looking instead at possible long-term consequences of drug use, a series of PET studies from 
the US National Institute of Drug Abuse has found that abstinent cocaine dependent patients 
as compared to healthy controls have elevated binding of the µ opioid receptor radioligand 
11C-carfentanil, which can be interpreted as an increased density of opioid receptors and/or 
lower concentrations of endogenous opioids (58). This elevated binding is seen both in 
subcortical structures and in the frontal lobes, and its magnitude is positively correlated with 
craving, increased risk of relapse and worse treatment outcome (59–61). Results in the same 
direction have been obtained in some neurochemical studies of rodents exposed to cocaine, 
but the pathophysiological mechanism behind this phenomenon remains unclear (62,63). 
Unfortunately, there have not yet been any studies of how amphetamine exposure influences 
brain opioid receptor levels. 
A more indirect way of studying the opioid system is through the use of drugs like naloxone 
and naltrexone, which both work as antagonists at the three classic opioid receptors µ, δ, and 
κ. Early research on rodents found that pretreatment with naloxone attenuated the locomotor 
effects of amphetamine (64). In a study from the 1990s using several behavioral paradigms 
and microdialysis in rats, naloxone attenuated behavioral effects and the DA-release caused 
by amphetamine (65). More recent studies have shown differential effects on a number of 
amphetamine-induced behaviors: for example, locomotor sensitization was attenuated (66), 
but conditioned place preference was unaffected by naltrexone pre-treatment (67).  
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A consistent finding from a number of human laboratory studies is that naltrexone pre-
treatment attenuates the subjective effects of amphetamine, both in healthy individuals and in 
amphetamine dependent patients (68–71)(Figure 2). In these studies, naltrexone weakened 
the subjective ratings of several amphetamine effects (e.g. euphoria, liking of the drug, 
wanting more, etc.), but did not affect its sympathomimetic properties, such as elevation of 
blood pressure and pulse. These findings were also replicated in Study II of this thesis. Since 
naltrexone does not alter the pharmacokinetics of amphetamine, this effect must be explained 
at a pharmacodynamic level, which was the rationale for Study I and II. 
 
 
Figure 2: Effect of naltrexone pre-treatment on subjective high from an oral dose of amphetamine (30 mg), given at 
the time point indicated by the arrow, in amphetamine dependent patients. Naltrexone significantly reduced the 
subjective effects of amphetamine in this sample, a finding that has subsequently been replicated a number of times. 
From Jayaram-Lindström et al. Neuropsychopharmacology 2008. 
2.5 NALTREXONE AS A TREATMENT FOR AMPHETAMINE DEPENDENCE 
Naltrexone has been approved by the United States Food and Drug Administration for the 
treatment of alcohol dependence since 1992, when two placebo-controlled, randomized 
clinical trials were published that found naltrexone to reduce the risk of relapse in alcohol 
dependent patients (72,73). Since then, more than 50 clinical trials have been published on 
naltrexone for alcohol dependence and there is strong evidence for its efficacy and safety, 
with relatively mild side effects (74). More recently, naltrexone has been approved in the US 
for the treatment of opioid dependence, as an alternative to the more established agonist 
maintenance treatments for this condition. In particular, an extended-release injectable 
formulation of naltrexone has been used successfully in the treatment of some cases of opioid 
dependence (75,76), although this formulation is not yet available for clinical use in the 
European Union. 
As mentioned above, a number of laboratory studies have found that naltrexone attenuates the 
subjective effects of amphetamine, both in healthy controls and in addicted patients. Some 
clinical trials have also investigated if it reduces the risk of relapse in amphetamine 
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dependence. In the first clinical trial, 80 amphetamine dependent patients were randomized to 
naltrexone or placebo and followed for 12 weeks (77). The results showed that naltrexone 
treated patients were less likely to relapse and also experienced less craving (Figure 3).  
 
Figure 3: Survival analysis, showing the percentage of amphetamine dependent patients with consecutive negative 
urine samples when treated with oral naltrexone or placebo. From Jayaram-Lindström et al. Am J Psychiatry 2008. 
Similar results were obtained in a 2010 trial, although this finding was less clear since the 
study was underpowered and investigated the effects of naltrexone and N-acetylcysteine 
combined versus placebo (78). A third study included patients with concurrent amphetamine- 
and heroin dependence and found that long-acting naltrexone improved retention in treatment 
and increased the proportion of drug-free urine samples as compared to placebo (79). In a 
more recent trial of naltrexone depot vs placebo for amphetamine dependence, there was very 
little amphetamine use regardless of treatment, and no advantage of naltrexone could be 
found (80). Another study of naltrexone depot for methamphetamine dependent patients did 
not find any reduction in methamphetamine use in the naltrexone group, as compared to 
placebo (81). 
In summary, there is strong evidence that naltrexone reduces the subjective effects of 
amphetamine and some evidence that it might reduce the risk of relapse in amphetamine 
dependence. While the trial-based evidence is mixed, it remains one of the most promising 
candidate drugs for the treatment of amphetamine addiction and further clinical trials are 
currently ongoing (82,83). At the same time, experimental research is targeting the 
mechanisms behind the effects of naltrexone, how the opioid system is involved in 
amphetamine dependence and in what ways pharmacologic manipulations of this system 
could have therapeutic potential, perhaps even beyond that of the non-selective opioid 
receptor antagonism of naltrexone. This thesis tackles some of these questions with the use of 
two different neuroimaging methods, which I will now introduce. 
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2.6 NEUROIMAGING IN ADDICTION RESEARCH 
Detailed structural imaging of the living human brain has been possible since the introduction 
of computerized tomography in the early 1970s. Functional neuroimaging is an even younger 
research field, but has grown rapidly since the first studies of the early 1980s. In the works of 
this thesis, we make use of PET and functional magnetic resonance imaging (fMRI). These 
are also the two functional imaging techniques that have been most widely used in addiction 
research so far. 
As mentioned earlier, PET is an imaging modality that, among other things, allows for 
neurochemical mapping and quantification of neurotransmitter release in the living human 
brain. This is made possible by the use of radioligands that are injected into the subject, pass 
the blood-brain-barrier and bind to targets of interest. The radioligand emits positrons, which 
collide with electrons in the tissue and give rise to photons detectable by a PET system. This 
data can then be used to calculate the binding of the radioligand in different parts of the brain, 
using kinetic models specific for each radioligand. For both of the radioligands used in this 
thesis, 11C-carfentanil in Study I and 11C-raclopride in Study II, a reference-tissue model can 
be used, where the radioligand density in the regions of interest (ROIs) are compared with a 
reference region with no (or very few) receptors of the type studied. Using such reference-
tissue models, we can calculate the non-displaceable binding potential (BPND), which 
represents the ratio of specifically bound to that of non-displaceable radioligand (84). 
For most ligands, the extent of specific binding depends not only on the density of receptors 
in the ROI, but also the levels of endogenous neurotransmitters that compete for the receptor 
binding sites. This is important to keep in mind when interpreting PET studies, particularly 
with case-control designs, where for instance cases with lower receptor density and reduced 
neurotransmitter levels may display similar BPND values as healthy controls, since these 
changes affect the binding in opposite directions. This ambiguity is less of a problem with 
experimental designs, such as Study I and II of this thesis, where each participant serves as 
his or her own control. Receptor densities typically change very slowly within the same 
individual, as compared to changes in neurotransmitter concentrations that occur on a 
timescale of seconds to minutes. Therefore, a lower BPND value in an experimental condition 
compared to baseline can often be interpreted as evidence that neurotransmitters have been 
released, occupying the relevant receptor sites so that the radioligand does not bind to the 
same extent. However, in some cases, differential internalization of receptors may constitute 
a remaining confounder working at a similar timescale as neurotransmitter release, and it is 
therefore of great value if PET findings can be validated with other techniques. 
PET has been of great importance in addiction research, not least in the study of the 
neurochemical effects of drugs of abuse, which up until the 1980s could not be studied in the 
living human brain. As mentioned above (Section 2.2), the mesolimbic DA system has 
received particular attention, but a steadily growing number of radioligands has continued to 
expand the possibilities of PET, which can now be used to study a large number of targets in 
the brain (85). As far as the opioid system is concerned, many different radioligands have 
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been proposed but only two of them have been more widely used and validated: 11C-
carfentanil and 11C-diprenorphine (86). 11C-carfentanil is a selective µ receptor ligand, while 
11C-diprenorphine has a similar affinity to all three classic opioid receptors. Since 11C-
carfentanil is more suitable for measuring endogenous opioid release in vivo, this was the 
ligand we chose in Study I to investigate the effects of an amphetamine injection on the brain 
opioid system (87). 
While PET can be very useful as a research tool, obstacles to its wider use include the 
potentially harmful health effects of ionizing radiation and the high costs associated with 
radioligand production. Because of this, many PET studies have very few participants and 
low statistical power. While the spatial resolution is steadily improving with new generations 
of PET systems, the temporal resolution is still relatively poor and a single measurement 
typically takes about an hour. 
Another imaging method that has been increasingly used since the 1990s is fMRI. While 
structural magnetic resonance imaging had already been in use for several years, the 
principles of BOLD (blood oxygen level-dependent) contrast were discovered in 1990 
(88,89). Using a strong magnet and a number of so-called radiofrequency coils, it was shown 
that an MR system can detect changes in the ratio of oxygenated to deoxygenated 
hemoglobin, since they have differing magnetic properties. A local increase in neural activity 
and metabolism increases oxygen extraction from the blood, raising the levels of 
deoxygenated hemoglobin. Because of the so called neurovascular reflex, neural activations 
are followed by increased local blood flow within a few seconds, effectively washing out the 
deoxygenated hemoglobin and instead raising the levels of oxygenated hemoglobin. This 
response can be detected with an MR system as an increased BOLD signal, which therefore is 
interpreted as an indirect measure of neural activity (90). 
The cellular mechanisms behind the neurovascular reflex are still being investigated and 
debated (91,92). The most important contributor to the changes in cerebral blood flow 
relevant for fMRI seems to be glutamatergic synaptic activity, but several other 
neurotransmitter systems and also different cell types may be involved. This means that the 
relationship between neural activity and vascular response can vary between different brain 
regions, but also between different individuals and different developmental stages (90). Our 
understanding of this variability is still limited and it is therefore hard to draw detailed 
conclusions about underlying neural activity based on BOLD responses alone. 
fMRI has several important advantages: it does not require any ligand or contrast injections 
and does not use ionizing radiation, which means that the same research subject can be 
studied on many occasions or for an extended period of time. Compared to PET, fMRI is 
cheaper and has superior temporal and spatial resolution. The ability to study the activity of 
the whole brain over time also allows for comparisons of the patterns of spontaneous signal 
change in different brain regions, which of course is not feasible with single-cell recordings 
or techniques with inferior resolution. This has led to one of the major findings so far in the 
fMRI field, namely the characterization of networks of functional connectivity, consisting of  
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brain regions with highly correlated spontaneous fluctuations in BOLD signal strength (93). 
Such networks are often studied with resting state fMRI, which does not mean that the brain 
is resting (its total metabolic demands actually change very little depending on what the 
person is doing), but only that the subject is at rest in the camera during data acquisition, not 
involved in any particular task. 
In addiction research, fMRI has often been used to study the neural correlates of different 
neuropsychological functions, such as impulsivity (94). It has also been important in the 
study of craving, since it allows the researcher to repeatedly expose the subject to, for 
instance, drug-related stimuli, and detect the neural reactivity to such cues (95). A paradigm 
of this kind was used in Study III and a modified version of it also in Study IV. 
A problem with fMRI is the complex relation of the BOLD signal to neural activity, as 
discussed above, which means that the results can be hard to interpret in neurophysiological 
terms. In contrast to PET, fMRI cannot map specific neurochemical systems or detect 
neurotransmitter release, which means that it cannot answer some of the critical questions in 
neuropsychopharmacology. There are also problems that arise from the huge amounts of data 
generated by fMRI, in particular the statistical problem of multiple comparisons that often 
result in underpowered studies, considering the small sample sizes typically used (96). The 
rapid development of different analytic methods without proper validation, combined with 
weak traditions of study pre-registration and data-sharing also contribute to current problems 
of inconsistency and bias in the fMRI literature (97–99). 
Finally, a more practical problem is the sensitivity of fMRI to artifacts, particularly head 
movements during image acquisition, which may cause so much noise that the signal of 
interest is lost (100). When preprocessing the data, movement artefacts can be corrected for 
up to a certain degree, but if the participant has moved a lot, the data may not be interpretable 
at all. 
2.7 CRAVING AND CUE REACTIVITY IN STIMULANT DEPENDENCE 
Intense craving for drugs has long been recognized as a common symptom in addictive 
disorders. As noted above, it serves as a diagnostic criterion for addiction in both DSM-5 and 
ICD-10, and is a central concept in almost all theoretical accounts of these disorders 
(101,102). Craving is also often the focus of clinical attention, both in psychological and 
pharmacological treatment (103). Despite all this, the concept of craving has been notoriously 
hard to define and measure in a valid and reliable way (104). In the year 2000, the prominent 
craving researcher Stephen Tiffany paraphrased the consensus statements from international 
meetings held on craving by the World Health Organization and others in the following way: 
“Although we do not know what craving is and we can establish no consensus about the best 
way to measure it or manipulate it, we certainly believe that more research should be 
conducted on this possibly, but not necessarily, important construct.” (104) 
While craving is still hard to define and measure, Tiffany and others have helped to advance  
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the field and craving has been the focus of intense research during the years since 2000, with 
growing use of neuroimaging technology to elucidate the biological mechanisms of craving. 
Because of the difficulties in obtaining a valid and reliable subjective measure of craving, a 
goal of these approaches is to develop a biomarker that would correlate with addiction 
severity and the risk of subsequent relapse (105). Such a biomarker could be useful both in 
the clinic to improve diagnostic accuracy and in research as a surrogate outcome when 
assessing new therapies. However, much research remains before these goals are fulfilled 
(105). 
Three principal factors eliciting craving in addicted subjects has been identified: stress (106), 
conditioned cues (102) and priming doses of the addictive drug (107). In study III, 
amphetamine dependent patients were exposed to drug-related cues and we will now briefly 
look at previous research using similar paradigms of cue-induced craving. 
Many studies have used fMRI to investigate the neural mechanisms of drug cue reactivity 
(108). Since most studies have been done in the United States, where cocaine is the 
dominating stimulant drug, only a few studies have included amphetamine users, and then 
mainly patients using methamphetamine through smoking, oral or intranasal administration 
rather than injecting amphetamine as is common in Sweden (109–111). The three studies 
published so far on methamphetamine users have all employed still pictures of drug taking or 
paraphernalia and contrasted this with exposure to neutral pictures. It is worth noting that two 
of these three studies did not have a DSM diagnosis of amphetamine dependence as an 
inclusion criterion and the cases represent mild or moderate addiction severity. 
 
Figure 4. Schematic picture of some of the neuroanatomical regions involved in cue reactivity in addiction. OFC = 
orbitofrontal cortex, VTA = ventral tegmental area. Adapted from Fowler et al. 2007 (112). 
Imaging studies of cue-induced stimulant craving (i.e. amphetamine, methamphetamine or 
cocaine) typically show activations of the nucleus accumbens/ventral striatum (VS), 
prefrontal cortex (PFC), amygdala and cingulate gyrus (see Figure 4)(95). However, the 
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results are quite heterogeneous, with activations of different brain regions reported in 
different studies. Several issues might contribute to explain this, not least the fact that early 
studies often were underpowered, used suboptimal study designs and inadequate statistical 
procedures for obtaining their results (113–115). However, all the variability is not caused by 
noise, since reviews of the literature have identified important patterns in the results. An 
interesting finding is that participants not seeking treatment for their addiction seem to react 
differently from participants who are active treatment-seekers (116). The former group is 
more likely to show activations of the PFC, a part of the brain involved in executive 
functions. It has been suggested that this could reflect the intention of the participants to seek 
out and take drugs after having been exposed to drug-related cues, while treatment-seeking 
individuals may not have such intentions (116).  
A more recent attempt at a quantitative meta-analysis of the field also concluded that 
prefrontal activations, particularly of the orbitofrontal cortex (OFC), differed between 
treatment seekers and non-treatment seekers (95). The authors also discuss alternative 
interpretations of this result, for example that treatment seekers might have diminished frontal 
functions as part of the adverse effects of drug intake that led them to seek treatment in the 
first place. To decide between these different alternative explanations, they need to be tested 
empirically, preferably with experimental manipulation of variables like expectancies or self-
control (95). So far, few studies have coupled their neuroimaging results to longitudinal data 
on the subsequent course of the participants disease (e.g. risk of relapse), which would be 
needed in order to establish cue reactivity as a valid biomarker for addiction (105). 
Some studies have investigated the effects of pharmacological treatments on cue reactivity. 
Of particular interest in this context are two fMRI studies of alcohol dependent patients 
which both found that naltrexone, as compared to placebo, attenuated cue-induced BOLD 
activations of prefrontal areas, and in one of the studies also the striatum (117,118). Also, one 
of the studies of methamphetamine users mentioned above also tested the effects of 
naltrexone on cue reactivity; while they did not find any effect on subjective measures of cue-
induced craving, naltrexone pre-treatment attenuated cue-induced activations of primary 
sensory and motor areas (110). The latter finding is somewhat surprising and of unclear 
significance, since these areas are not typically implicated in drug cue processing (95). In 
other words, the effects of naltrexone on cue-induced craving and neural reactivity in 
amphetamine dependence are still quite unclear. 
2.8 SUBLIMINAL CUE REACTIVITY 
As mentioned above, exposure to drug-related conditioned cues is a common cause of 
craving, but patients quite often report that strong feelings of craving “just came over me” for 
no apparent reason. An intriguing hypothesis is that such reactions can be elicited by cues 
that are so subtle that they are only perceived subliminally, i.e. without reaching conscious 
awareness (119). 
Subliminal processing of visual stimuli has been studied with several different methods, one 
of them being backward visual masking. In this paradigm, a very brief visual stimulus (the 
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target) is immediately followed by another visual stimulus (the mask), which disturbs the 
perception of the target stimulus so that it does not reach conscious awareness (120). Within 
emotional psychology, visual masking has been of particular importance in studies of fear, 
where the amygdala has been shown to play a central role in a subcortical network that is able 
to detect fear-relevant stimuli and elicit fear responses in a fast and nonconscious manner 
(121). This system has probably been of great evolutionary importance as a quick way of 
detecting and reacting to the presence of predators, without the need for more elaborate, 
cortical processing of warning signs in the environment. 
There are many studies on subliminal fear processes, but a number of studies have also 
investigated positive motivational systems, not least in addictive disorders. In recent years, 
visual masking has been employed in some fMRI studies of substance dependent patients. In 
2008, a pilot study of cocaine patients reported activation of several limbic structures when 
cocaine patients were exposed to masked visual cocaine cues (119). In 2014, the same 
research group published two more studies: one suggesting that the GABAB receptor agonist 
baclofen could block this subliminal cue reactivity (122) and another where cannabis patients 
were found to have similar levels of subliminal cue reactivity as the cocaine patients (123). 
So far, the only published attempt at replicating these results in another laboratory is a study 
of nicotine dependent patients. In the latter study, the right amygdala showed a decreased 
BOLD signal in response to masked smoking-related images, a reaction opposite to that 
expected (124). Prior to Study IV, there were no published studies on subliminal cue 
reactivity in amphetamine dependent patients. 
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3 AIMS 
The aim of this thesis is to investigate the role of the opioid system in amphetamine 
dependence and thereby elucidating the therapeutic mechanism of action of the opioid 
antagonist naltrexone. Specifically, the four studies aimed to test the following hypotheses: 
Study I:  That an amphetamine injection gives rise to an endogenous opioid release in healthy 
human subjects. 
Study II: That naltrexone attenuates amphetamine-induced striatal DA release in rodents and 
healthy human subjects. 
Study III: That naltrexone attenuates craving and neural cue-reactivity in amphetamine 
dependent patients. 
Study IV: That subliminal drug cues as compared to neutral cues activate motivationally 
relevant brain structures in amphetamine dependent patients, but not in healthy controls, and 
that naltrexone attenuates this reaction. 
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4 METHODS 
In the studies included in this thesis, we made use of the neuroimaging methods PET and 
fMRI, which have already been introduced above. In Study II, we also employed in vivo 
microdialysis to measure DA release in rats. In this chapter, I will present in more detail the 
methods used in each of the studies, and also discuss ethical issues relevant to the studies. All 
studies were approved by the Stockholm Ethics Review Board and the Swedish Medical 
Products Agency, and each subject provided written informed consent before any study 
specific procedures were made. Since Study I and II used ionizing radiation, they were also 
approved by the Radiation Safety Committee of the Karolinska University Hospital Solna. 
4.1 STUDY I: EFFECTS OF AMPHETAMINE ON THE ENDOGENOUS OPIOID 
SYSTEM: A 11C-CARFENTANIL PET STUDY 
In Study I, we investigated if amphetamine activates the brain opioid system. As mentioned 
above, the opioid antagonist naltrexone has been shown to attenuate the effects of 
amphetamine, and a possible explanation for this could be that amphetamine activates the 
opioid system, an activation that of course would be inhibited by an opioid antagonist. Some 
rodent studies have suggested such a mechanism (57) and we aimed to test the hypothesis 
that an intravenous dose of amphetamine would cause an endogenous opioid release in the 
brain of healthy human subjects. 
Subjects: Ten healthy men, aged 23-31, were recruited via flyers and by word-of-mouth at 
Karolinska Institutet. Before inclusion in the study, all participants went through a screening 
procedure. Exclusion criteria included (1) DSM-IV diagnosis of major Axis-1 psychiatric 
disorder including any history of substance use disorder (including nicotine), (2) use of a 
psychoactive substance within the past 30 days, (3) history of serious medical conditions, (4) 
positive result on alcohol breath analyzer at the test sessions, (5) traces of opiates, cannabis, 
amphetamines or benzodiazepines in the urine at screening or during test days. The subjects 
also underwent a structural MR scan to exclude intracranial pathology and obtain anatomical 
references for definition of ROIs to be used when analyzing the subsequent PET 
examinations (see below). The participants were paid an equivalent of €500 for their 
participation. 
Methods: Study I was designed as a cross-over randomized controlled trial, where each 
participant went through three PET examinations with 11C-carfentanil: at baseline, after an 
injection of amphetamine (0.3 mg/kg body weight) and after an injection with placebo. The 
order of amphetamine and placebo was randomized and double-blind, to avoid confounding 
with expectation effects. The examinations for each subject were done approximately one 
week apart, although three of the examinations were delayed for technical reasons and instead 
performed after 20-40 days.  
To study endogenous opioid release, we used PET with 11C-carfentanil, a radioligand specific 
for µ opioid receptors (125). This ligand has been used extensively since the 1980s and has 
been shown to have excellent test-retest reliability, which makes it well suited for studies 
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with repeated measures, such as cross-over experiments (126). There is also a validated 
method for estimating its binding with a simplified reference-tissue model, which means that 
there is no need for arterial blood sampling to calculate its binding potential (127). In several 
earlier studies, 11C-carfentanil has been used successfully to detect changes in endogenous 
opioid release in response to behavioral or pharmacological challenges (126,128–130). 
All PET examinations were performed using a high-resolution research tomograph (Siemens 
Molecular Imaging, Germany). For each subject, an individual helmet was made and attached 
to a holder on the coach to minimize head movement. After a six-minute transmission scan 
using a single 137Cs source, the study drug (amphetamine/placebo) was injected into an 
intravenous catheter and flushed with saline. Two minutes later, 11C-carfentanil was 
administered as a rapid bolus and flushed with saline. List-mode data were acquired for 69 
min, starting at the time of ligand injection. 
Data analysis: PET images were reconstructed from a series of 16 time frames, including 
modelling of the point spread function, after correction for attenuation, randoms and scatter. 
This reconstruction procedure yields a spatial resolution of 1.5 mm (131). PET images were 
corrected for head movement using frame-by-frame realignment (132) using the first frame as 
reference. 
When analyzing the data, ROIs were delineated on the MR images of each individual subject 
using the Human Brain Atlas software (133)(Figure 5). Ventral striatum was chosen as the 
primary ROI, while a secondary analysis included other brain regions involved in drug abuse 
and reward, i.e. associative and sensorimotor striatum, prefrontal cortex (divided into 
orbitofrontal, dorsolateral and medial), anterior cingulate cortex, hippocampus and amygdala. 
The definitions of ROIs were based on previously published guidelines (134–138). 
 
Figure 5: T1-weighted magnetic resonance image, coronal slice through the striatum, with regions of interest 
delineated in red (left), and 11C-carfentanil positron emission tomography image, corresponding slice (right). The high 
levels of 11C-carfentanil binding in the striatum, particularly in its ventral parts, correspond to the high density of µ 
opioid receptors in this region. From Guterstam et al. Int J Neuropsychopharm 2013. 
PET images were then co-registered to the MR image using SPM 5. Correction for partial 
volume effects was done with the method described by Meltzer et al. (139). Quantitative 
analysis was performed using the simplified reference tissue model with the occipital lobe as 
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reference region, an approach that has previously been validated for 11C-carfentanil 
(126,127). BPND was the parameter of interest, representing the ratio at equilibrium of 
specifically bound to that of non-displaceable radioligand (84). BPND measures from the 
baseline, placebo and amphetamine conditions were analyzed with repeated measures 
analysis of variance (ANOVA) for effect of treatment. 
4.2 STUDY II: EFFECTS OF NALTREXONE ON AMPHETAMINE-INDUCED 
DOPAMINE RELEASE 
In study II, we aimed to explore the effects of naltrexone pre-treatment on amphetamine-
induced DA release in the striatum. Since naltrexone weakens the subjective effects of 
amphetamine, and some of these effects have been correlated with striatal DA release, our 
hypothesis was that naltrexone as compared to placebo would attenuate the DA-release 
caused by amphetamine. 
In order to study DA release in humans, we used PET and the DA D2 receptor radioligand 
11C-raclopride. The sensitivity of this radioligand to stimulant-induced changes in brain DA 
concentration is well-established (140,141). Since DA release might be sensitive to 
expectations of amphetamine (142), we included a placebo condition in the study. For ethical 
reasons, only a limited strength and number of doses of amphetamine may be given to human 
subjects in an experimental setting. Therefore, we used a rat model to study both the acute 
and the more long-term effects of amphetamine, using in vivo microdialysis to analyze brain 
DA levels. 
4.2.1 11C-raclopride PET 
A cross-over randomized, placebo-controlled, double-blind design was used to test the 
hypothesis that pre-treatment with naltrexone would attenuate the brain DA release induced 
by amphetamine. 
Subjects: Seven healthy males aged 20-45 years were recruited via flyers posted at Karolinska 
Institutet. The sample size was based on previous studies demonstrating significant effects of 
amphetamine on 11C-raclopride binding in healthy controls (25,33,142), as well as earlier 
work from our own group on naltrexone and amphetamine (68,69). Exclusion criteria were 
similar to those in Study I and included (1) DSM-IV diagnosis of major Axis-1 psychiatric 
disorder including any history of substance use disorder (including nicotine), (2) use of a 
psychoactive substance within the past 30 days, (3) history of serious medical conditions, (4) 
positive result on alcohol breath analyzer at the test sessions, (5) traces of opiates, cannabis, 
amphetamines or benzodiazepines in the urine at screening or during test days. All 
participants provided written informed consent and were paid an equivalent of €500 for their 
participation. 
Methods: Prior to the PET measurements, all subjects underwent a structural MR scan (1.5 T) 
to exclude intracranial pathology and obtain anatomical references for definition of ROIs. In 
total, each subject underwent three PET examinations with 11C-raclopride, approximately one 
week apart: at baseline, after placebo plus amphetamine administration, and after naltrexone 
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plus amphetamine administration (denoted here as baseline, placebo+amphetamine, and 
naltrexone+amphetamine, respectively). The order of the two latter examinations was 
randomized. 
On test days, subjects arrived at the laboratory at 8:00 am and received a standardized 
breakfast. Subjective and physiological measures were evaluated throughout the experimental 
procedure. At 9:00 am, the participants received either a capsule of naltrexone (50 mg) or 
placebo. One hour post ingestion of study medication, they underwent a PET examination 
with 11C-raclopride, using the ECAT HR 47 (CTI/Siemens, Knoxville, TN) PET system run 
in 3D mode. Prior to each emission scan, a transmission scan was performed for attenuation 
correction. The subjects received an intravenous dose of amphetamine (0.3 mg/kg 
bodyweight), immediately followed by a saline solution of 11C-raclopride (223–268 MBq, 
specific radioactivity 193–1131 GBq/µmol) injected as a bolus. The cannula was then flushed 
with 10 ml saline. Immediately following 11C-raclopride administration, PET emission data 
was obtained for 51 min (143). To minimize movement artifacts, an individual plastic helmet 
was made for all participants and used together with a head fixation system. The 
reconstructed data were displayed as 47 horizontal sections with a center-to-center distance of 
3.125 mm. 
A visual analog rating scale (VAS) was administered to describe the subjective drug effects. 
The VAS comprised four scales: ‘feel the drug’, ‘like the effect’, ‘feel aroused’ and ‘want 
more’, providing a composite measure of subjective effects. The subjects rated their 
experiences starting at the time of naltrexone/placebo administration and continuing at 
designated time points. To measure the physiological effects of amphetamine, heart rate and 
blood pressure were recorded manually at the same time points as the subjective measures. 
Data analysis: ROIs were manually delineated on individual structural MR images, based on 
previously published guidelines (137,144) in which the striatum is divided into limbic, 
associative and sensorimotor subregions based on their differential connectivity (145). The 
same ROIs were used for all three examinations and all ROIs were combined to create a ROI 
for the whole striatum. The MR images were reoriented to the AC-PC plane and then used for 
co-registration to PET images using SPM 2. The average values of right and left ROIs were 
used to increase the signal-to-noise ratio for the quantification. A ROI for cerebellum was 
drawn below the appearance of the petrosal bone in five slices, corresponding to a thickness 
of 10 mm. ROIs were applied to the PET images using the co-registration parameters to 
extract regional time activity curves. 11C-raclopride BPND was calculated using the simplified 
reference tissue model (146) with cerebellum as a reference region. 
Statistical evaluation of BPND data for each ROI was conducted using two-way repeated-
measures ANOVA. Three comparisons of binding potential values were estimated by the 
ANOVA: (1) baseline vs. amphetamine, (2) baseline vs. naltrexone+amphetamine, (3) 
placebo+amphetamine vs. naltrexone+amphetamine. Condition by region interactions in the 
ANOVA were investigated further with post hoc t-tests. All statistical tests were two-tailed 
with a significance level conventionally set at p < 0.05. The secondary outcome of subjective  
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measures was defined as the mean score of the four VAS items for the various time points 
during each test day, comparing the naltrexone+amphetamine and placebo+amphetamine 
conditions. A group composite score was calculated as an aggregate of the mean scores for 
each time point. This score was compared between the two conditions with repeated 
measures ANOVA. 
4.2.2 Microdialysis 
We used in vivo microdialysis to investigate the effects of naltrexone on amphetamine-
induced DA release in freely moving rats. First, two different acute amphetamine doses were 
tested. In a second experiment, we investigated the effects of amphetamine reinstatement, i.e. 
a challenge dose of amphetamine after a period of chronic treatment followed by abstinence. 
Methods: Male Wistar rats (250-380 g) were housed four per cage in a temperature (±21 ºC) 
and humidity (±40-50%) controlled environment on a 12 h light/dark cycle (lights on 7:00 
AM). Food and water were available ad libitum. All experiments were conducted during the 
light phase of the cycle. Animals were handled in accordance with the guidelines of the 
Swedish National Board of Laboratory Animals and the study was approved by the Ethical 
Review Board of Stockholm (acute experiment) or Gothenburg (chronic experiment), 
Sweden. 
Dexamphetamine sulphate and naltrexone were dissolved in physiological saline (sodium 
chloride 0.9% (w/v)). All drugs were administered intraperitoneally (i.p.), and injected at a 
volume of 1 or 2 ml per kilogram of body weight. 
For the surgical procedure, rats were anaesthetized with a mix of fentanyl citrate (0.39 
mg/kg) and fluanisone (12.5 mg/kg) and midazolam (6.25 mg/kg) diluted in distilled water 
(1:1:2; 5 ml/kg i.p.) or by isoflurane and mounted in a stereotaxic frame. Dialysis probes 
were implanted in the nucleus accumbens with stereotaxic coordinates anteriorposterior: +1.6 
mm: mediolateral - 1.4 mm: dorsoventral -8.2 mm relative to bregma and the dural surface, in 
accordance with an anatomical atlas (147). After surgery, animals were individually housed 
and allowed 2 days of recovery before initiation of the experiment. 
The microdialysis experiments were conducted approximately 48 h after surgery. Dialysis 
occurred through a semi-permeable membrane with an active surface length of 2-2.25 mm. 
The dialysis probe was perfused with a physiological solution at a rate of 2 or 2.5 µl/min set 
by a micro infusion pump. Dialysate was collected over 15 min intervals (37.5 µl) in the two 
acute dialysis studies and over 20 min intervals (40 µl) in the chronic dialysis study, after 
which the samples were injected into a high-performance liquid chromatography system. On-
line quantification of DA in the dialysate was accomplished by electrochemical detection. 
After baseline measurements in the acute dialysis studies, rats were treated with either 
naltrexone (3 mg/kg i.p) or saline (1 ml/kg i.p) 30 minutes before given an amphetamine (0.5 
or 2 mg/kg i.p) or saline injection (1 ml/kg i.p). In the chronic dialysis study, rats were 
conditioned to amphetamine using a protocol which induces robust locomotor sensitization to 
amphetamine (66). Briefly, rats received daily injections of either saline or amphetamine (2  
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mg/kg) for ten consecutive days after which the animals were left untreated for another ten 
days. Surgery was performed eight days into the drug free period. In the following 
microdialysis experiment, the rats received an injection with naltrexone or vehicle, followed 
40 min later by a saline injection for the previously saline treated rats and amphetamine (0.5 
mg/kg i.p.) for the previously amphetamine treated rats. Dialysate was collected for 180 min 
after the last drug administration. 
Data analysis: DA levels were expressed and statistically analyzed as percent of baseline 
levels. Baseline was defined as the average of the four dialysate samples collected 
immediately before the first injection. The mean percent changes from baseline were then 
calculated for each 15/20 min sample for all rats in each group. Data were analyzed by one- 
or two-way ANOVA followed by planned comparison using the STATISTICA software. 
4.3 STUDY III: EFFECTS OF NALTREXONE ON CUE REACTIVITY IN 
AMPHETAMINE DEPENDENCE: AN FMRI STUDY 
This study was designed as a randomized, double-blind clinical trial with two parallel groups 
of amphetamine dependent patients. Each patient received one oral dose of naltrexone (50 
mg) or placebo and then went through an fMRI examination, investigating the effect of 
naltrexone on drug cue reactivity and craving. The study was preregistered in the EU Clinical 
Trials Register (EudraCT 2010-021384-33) and performed according to ICH guidelines for 
Good Clinical Practice, with external monitoring by the Karolinska Trial Alliance. 
Subjects: 40 male, non-treatment-seeking amphetamine users aged 20-65 were recruited via 
advertisement and word of mouth at the needle exchange program and in shelters in the 
Stockholm region. All participants were screened by a study physician, including psychiatric 
assessment with the Structured Clinical Interview for DSM-IV, Axis 1 (SCID-1), and detailed 
assessment of substance use history and other variables with the Addiction Severity Index. 
Inclusion criteria included DSM-IV diagnosis of amphetamine dependence since at least two 
years, history of intravenous amphetamine use, amphetamine use for minimum of 12 times in 
the last 12 weeks, and having been drug free 1-30 days (minimum 24 hours). Exclusion 
criteria were other ongoing substance dependence (except nicotine), schizophrenia or bipolar 
disorder I, left-handedness, clinical signs of amphetamine intoxication at the day of testing, 
traces of cannabis, opiates, cocaine or benzodiazepines in the urine at the day of testing, 
traces of alcohol as measured by breathalyser at the day of testing or presence of severe 
somatic disorder (e.g. renal or hepatic failure). Patients with contraindications to MRI (e.g. 
cardiac pacemaker, severe claustrophobia) or the study medication (e.g. regular opioid use or 
known hypersensitivity) were also excluded. All patients were compensated for their 
participation with food coupons to the value of €150. 
Study procedures: After a first screening visit, eligible patients were scheduled for a test day. 
Having arrived in the clinic on the test day, the patients were asked for a urine test to exclude 
current use of drugs other than amphetamine. If the result was negative and a breathalyzer 
test showed no trace of alcohol, the patient was included in the study and randomized to a 
capsule of 50 mg naltrexone or an identical capsule with placebo. After an interval of at least  
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60 minutes, the MRI procedures were started. 
The experiment described here consisted of the patients seeing film clips depicting drug 
related scenes (i.e. people preparing and taking drugs) or neutral scenes (e.g. old people 
drinking coffee or chatting). Nine film clips of each type, lasting 16 seconds each, were 
shown in a pseudo-randomized order. After every clip, the participants were asked to rate 
with a trackball their level of amphetamine craving on a visual analog scale on the screen, 
with 0 in one end representing no craving at all and 100 in the other end representing the 
maximum level of craving imaginable. In total, the experiment lasted for 7 minutes. 
After the examination, the patient was debriefed, asked about lingering craving and possible 
adverse events. All patients were asked if they were interested in clinical follow-up at the 
Stockholm Centre for Dependence Disorders. 
Magnetic resonance imaging: MRI examinations were performed with a 3 T instrument (GE 
MR750 Discovery) at the Karolinska MR Research Center. Each subject went through a total 
of four fMRI paradigms and structural imaging, lasting for about 50 minutes in total. The 
experiment described here as Study III was the last to be performed before the structural 
imaging and was preceded by a resting state examination and two different paradigms with 
still pictures. 
Data analysis: Data was analyzed with SPM 12. Using a standard preprocessing approach, 
the functional images were realigned, co-registered to the participant’s structural image, 
segmented and smoothed with a 7 mm FWHM Gaussian kernel. The images were then 
normalized to an MNI template. Since movement artefacts represent a major problem in 
fMRI, particularly for patient populations, we decided to set a limit for the framewise 
displacement (FD), such that no more than 25% of the volumes were allowed to have a FD 
>0.3. 
The functional data were analyzed as a block design using the general linear model and 
random field theory as implemented in SPM 12. In the first-level analysis, we defined 
separate regressors for the intervals that represented the drug and neutral movies, and defined 
linear contrasts in the general linear model to test our hypotheses. The resulting contrast 
images from all patients were entered into a random effects group analysis to accommodate 
intersubject variability and to compare the naltrexone vs. placebo groups.  
For the statistical inference, we applied corrections for multiple comparisons within the 
appropriate search space using Family-Wise Error (FWE) correction with level of 
significance set at p < 0.05. We pre-specified ROIs based on the prior literature on cue 
reactivity in stimulant dependence (95). In these regions, which included the VTA, striatum, 
anterior cingulate cortex, OFC and medial prefrontal cortex, we corrected for multiple 
comparisons within small volumes. For areas outside our ROIs, we corrected for multiple 
comparisons using the whole brain as search space. 
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4.4 STUDY IV: SUBLIMINAL CUE REACTIVITY 
This study was part of the same project as Study III and used the same cohort of 
amphetamine dependent patients. For Study IV, we also included 30 healthy controls. Both 
patients and controls received one oral dose of naltrexone (50 mg) or placebo before the 
fMRI examination, which in this case aimed to investigate if subliminal drug cues would 
activate motivational systems of the brain. 
Subjects: 40 male, non-treatment-seeking amphetamine users aged 20-65 were included, as 
described above for Study III. In addition, we included 30 healthy controls, who were also 
male, aged 20-65. Exclusion criteria for the healthy controls included any history of 
substance use disorder or other psychiatric diagnoses, current use of any medication, left-
handedness or contraindications for MRI or the study medication. All participants were 
compensated for their participation with food coupons to the value of €150. 
Study procedures: The basic procedures were similar to Study III. After a first screening visit, 
eligible participants were scheduled for a test day. After inclusion, each participant was 
randomized to a capsule of 50 mg naltrexone or an identical capsule with placebo. After an 
interval of at least 60 minutes, the MRI procedures were started. 
The experiment of Study IV consisted of exposing the participants to drug-related or neutral 
pictures for a very brief interval, 13.3 ms. This was then followed by another picture, the 
“mask”, either immediately or after an interval of 94 ms with a black screen (this interval 
would presumably attenuate the masking effect and could therefore be used as a supraliminal 
perceptual control). After the mask, a fixation cross was shown on the screen for a variable 
interval of 2-10 s. An overview of the paradigm is shown in Figure 6. 
 
Figure 6: Subliminal cue paradigm of Study IV: each trial consisted of a very brief cue, with either drug-related or 
neutral content, followed by a masking picture and then a fixation cross until the appearance of the next cue. 
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Magnetic resonance imaging: MRI examinations were performed with a 3 T instrument (GE 
MR750 Discovery) at the Karolinska MR Research Center. Each subject went through a total 
of four fMRI paradigms and structural imaging. The experiment described here was the first 
to be performed, preceded only by a resting state examination. 
Data analysis: The preprocessing procedures were identical to those of Study III. In Study 
IV, however, the functional data were analyzed in an event-related design using the general 
linear model, where the primary contrast was Active with immediate mask > Neutral with 
immediate mask. The statistical approach was identical to Study IV, with FWE correction for 
multiple comparisons and level of significance set at p < 0.05. 
4.5 ETHICAL ASPECTS 
The studies described in this thesis involve several potential ethical problems that need to be 
discussed. Before the start of each study, we described and analyzed these ethical issues in 
the applications to the Ethics Review Board. Here, I will briefly discuss the most important 
points. 
In Study I and II, we gave intravenous injections of dexamphetamine to healthy participants, 
which of course could be seen as problematic since amphetamine is an addictive substance 
that might cause adverse effects. This dilemma was handled by making sure that all 
participants were carefully screened by a study physician, ruling out somatic or psychiatric 
conditions that could increase the risk of adverse effects. All substance use disorders, both in 
the participants and in their first-degree relatives, were considered exclusion criteria. The 
risks of amphetamine intake were also minimized by giving a quite low dose, 0.3 mg/kg body 
weight, which is lower than a normal dose of stimulant medication for ADHD. Since the drug 
was administered in conjunction with PET examinations, the participants were carefully 
monitored for more than one hour post-injection by qualified staff in a research center in the 
middle of the Karolinska University Hospital, where possible adverse reactions could be 
handled effectively. With these precautions, our conclusion was that the risks involved in 
giving amphetamine to healthy persons were very small. In the end, no serious adverse events 
were seen in Study I or II. 
In Study II and III, we gave a single, oral dose of naltrexone (or placebo) to healthy 
volunteers and amphetamine dependent patients. This could hardly be seen as ethically 
problematic, since naltrexone is a well-known medication that has been in clinical use for 
many years and the risk for any serious adverse events from a single dose is minimal. The 
only major side-effect that could be of importance is the risk of inducing acute opioid 
withdrawal symptoms, if someone with ongoing opioid use would take naltrexone. Although 
not dangerous in a medical sense, such a reaction could be highly unpleasant. Therefore, all 
participants were asked about current opioid use and also asked to leave a urine sample to 
objectively exclude this before randomization. 
Study II also included work on rats, that were exposed to study drugs and examined with 
microdialysis. Although this might be seen as ethically problematic, we saw no feasible way  
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of answering the relevant research questions without the use of such validated animal models. 
All animals were housed and treated in accordance with current national guidelines, and the 
procedures were approved by the regulatory board. 
Study III and IV included amphetamine dependent individuals, which in itself raises certain 
ethical problems. A point of discussion in medical ethics has been if drug dependent patients 
are competent and autonomous enough to leave a truly informed consent, for example to 
participate in research projects (148,149). But the fact that drug addicted patients may have 
lost control over certain parts of their lives (i.e. the substance use) does not entail that they do 
not know their best interest and are able to act accordingly in other situations. Study III and 
IV also did not involve the administration of any addictive substance, a situation that could be 
seen as particularly problematic (148). When meeting the potential participants, we made 
sure they understood the full meaning of participation before they were allowed to sign the 
consent form. 
One part of Study III that could be seen as controversial is that we exposed amphetamine 
dependent subjects to drug-related cues in order to induce craving, a procedure which might 
increase the risk of relapse to drug abuse. However, earlier studies addressing this issue have 
not found any elevated risk of relapse in stimulant dependent patients exposed to drug cues in 
experimental settings (150,151). This is also in accordance with our experience from earlier 
studies of cue-induced craving: in an experimental setting, craving vanishes rather quickly 
and is often completely gone before the participants leave the research facility (43,152). The 
clinical milieu probably attenuates the feelings of craving and in case any adverse reactions of 
this nature would occur, an experienced physician was always present to support the patient. 
To make sure that we did not increase the risk of relapse in stable, drug-free individuals, we 
chose only to include people with long-term, active amphetamine dependence (at least 12 
amphetamine intakes during the last 12 weeks and not more than 30 days of continuous 
abstinence). 
The participants in the study had at least one free visit to the study physician for assessment 
of physical and mental health and problems related to substance use. Although the patients 
were not actively treatment-seeking, a visit of this kind can sometimes be of help, 
constituting a positive first contact with organized health care. Having participated in the 
study, the patients were offered a referral to their local substance dependence clinic. 
In conclusion, we estimated the risks for the participants in Study III and IV to be small and 
the moderate expected benefits for them to be bigger. Since we could not see any relevant 
arguments against the study in a larger context, we concluded that it was ethically defensible. 
No serious adverse events were seen in Study III or IV.  
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5 RESULTS 
5.1 STUDY I 
In Study I, all 10 participants included in the study performed all examinations according to 
the protocol (apart from the time delay in performing three of the examinations, as already 
mentioned in the methods chapter, section 4.1). As expected, within 1-2 minutes the 
amphetamine injection caused strong subjective effects in all the subjects. Ratings of how 
much the subjects “felt” the drug effect ranged from 50 to 100 (mean 88 ± 16), feeling of 
“high” from 30 to 90 (mean 66 ± 22) and how much they wanted more of the drug from 0 to 
100 (mean 64 ± 33). Placebo ratings were between 0 and 10 for all three questions. No 
serious adverse events occurred during the study.  
When analyzing the PET data, repeated measures ANOVA revealed no significant effects of 
amphetamine compared to placebo on 11C-carfentanil BPND in the ventral striatum (Figure 7). 
The mean difference in BPND in this region was -0.037, with a 95% confidence interval of -
0.186 to 0.111 (or -6.4 to 3.8%). Similar results were found in the other regions of the 
striatum, prefrontal cortex, amygdala and hippocampus. 
 
Figure 7: Individual measures of 11C-carfentanil binding potential (BPND) in the ventral striatum at baseline, after 
placebo and after amphetamine injection. 
The BPND values in the different regions were comparable to the ones obtained in a recent 
test-retest-study of 11C-carfentanil (126). However, as can be seen in Figure 6, there was 
some variability in BPND between the conditions for several participants. In an exploratory 
analysis, we examined if these individual differences were correlated with subjective ratings 
of amphetamine effects, but no such correlation was found. Neither was there any effect of 
order between the amphetamine and placebo examinations, which means it did not matter if 
you had the amphetamine first and then placebo at the next occasion or vice versa. 
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5.2 STUDY II 
5.2.1 11C-raclopride PET 
Subjective effects: The amphetamine injections caused strong subjective effects in all of the 
participants. Repeated measures ANOVA revealed a main effect for treatment condition (F = 
482.1; p < 0.001), such that the placebo+amphetamine condition produced a significantly 
stronger subjective drug effect than the naltrexone+amphetamine condition. In other words, 
naltrexone reduced the subjective effects of amphetamine (Figure 8), just as previously 
shown in several other studies. 
 
Figure 8: Subjective effects of an amphetamine injection (0.3 mg/kg bodyweight) at time point=0, after pretreatment 
with naltrexone or placebo. Values denote mean ± standard error of the mean for the composite score at each time 
point, defined as the average values of the four visual analog rating scales: ‘feel the drug’, ‘like the effect’, ‘feel 
aroused’ and ‘want more’. NTX=naltrexone, Amph=amphetamine. 
Effects on dopamine release: Two-way repeated measures ANOVA revealed main effects of 
condition (F = 9.76, p = 0.015), brain region (F = 67.76, p < 0.001) and a condition-by-region 
interaction (F = 4.21, p = 0.024) on 11C-raclopride BPND. Post hoc paired t-tests demonstrated 
significantly decreased BPND in all striatal ROIs for both placebo+amphetamine and 
NTX+amphetamine as compared to baseline, indicating increased DA levels in the striatum 
after the amphetamine injection, as was expected. However, there was no significant 
difference in BPND between placebo+amphetamine and naltrexone+amphetamine (Figure 9). 
The results were similar for all subregions of the striatum. 
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Figure 9: 11C-raclopride binding potential (BPND) in the ventral striatum at baseline, after placebo+amphetamine and 
naltrexone+amphetamine. Figures represent mean and 95% confidence intervals. Amph=amphetamine, 
NTX=naltrexone. 
5.2.2 Microdialysis 
We investigated the effects of naltrexone pretreatment on the dopamine release induced by 
amphetamine, using in vivo microdialysis in Wistar rats. All measurements were made in the 
nucleus accumbens. We tried two different doses of amphetamine in a model of acute 
amphetamine intake and one dose in model with chronic amphetamine exposure. 
Acute model: Two-way ANOVA of the data from the acute amphetamine (0.5 mg/kg) 
experiment revealed significant time, treatment and interaction effects (Finteraction(42,252) = 
4.498, p<0.0001). Amphetamine as compared to saline caused a significant increase in DA 
concentrations after administration (Figure 10). Pre-treatment with naltrexone (3 mg/kg) did 
not significantly influence amphetamine-induced DA release. 
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Figure 10: Effects of an acute amphetamine injection (0.5 mg/kg) on dopamine concentrations in the nucleus 
accumbens, as measured with microdialysis in Wistar rats. Naltrexone/vehicle pretreatment was given at time 
point=0, while amphetamine/vechicle was given at time point=30 min. Amphetamine increased dopamine levels but 
naltrexone pretreatment had no effect as compared to vehicle. NTX=naltrexone, Veh=vehicle, Amph=amphetamine. 
When amphetamine was administered at a dose of 2.0 mg/kg, two-way ANOVA revealed 
similar effects as with the lower dose (Finteraction(42,248) = 23.39, p<0.0001). At this higher 
dose, amphetamine caused a robust increase of DA output compared to saline (p<0.001), an 
effect that lasted up to two hours (Figure 11). NTX (3 mg/kg) pre-treatment did not affect the 
amphetamine-induced DA output at any time point. 
 
Figure 11: Effects of an acute amphetamine injection (2.0 mg/kg) on dopamine concentrations in the nucleus 
accumbens. Naltrexone/vehicle pretreatment was given at time point=0, while amphetamine/vechicle was given at time 
point=30 min. Amphetamine caused a highly significant increase in dopamine levels, but naltrexone pretreatment had 
no effect as compared to vehicle. NTX=naltrexone, Veh=vehicle, Amph=amphetamine. 
 
Chronic model: In the chronic model, with daily administration of amphetamine (2 mg/kg) 
for ten days, followed by a drug free period of ten days and then reinstatement of 
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amphetamine (0.5 mg/kg), two-way ANOVA revealed significant time, treatment and 
interaction effects (Finteraction (27,234) = 8.365, p<0.0001). Post hoc analysis revealed that 
amphetamine significantly increased DA output 20 minutes after administration compared to 
baseline (Figure 12). There was also a significant difference between naltrexone+vehicle and 
naltrexone+amphetamine treatment (p=0.014) and between vehicle+amphetamine and 
naltrexone+amphetamine treatment (p=0.030). Effectively, naltrexone pre-treatment 
attenuated the amphetamine-induced DA elevation by approximately 50% in this model with 
chronic amphetamine administration. 
 
Figure 12: Dopamine concentrations in the nucleus accumbens after reinstatement with amphetamine (0.5 mg/kg), 
following previous chronic amphetamine administration and 10 days of abstinence before the experiment. Naltrexone 
significantly reduced amphetamine-induced dopamine release in this model. 
5.3 STUDY III 
This study included 40 male patients with amphetamine dependence. They were on average 
44 years old, with long histories of intravenous amphetamine use. Most were unemployed 
and had a criminal history, having spent a mean of 4.5 years incarcerated. There were no 
significant differences in important baseline variables between the naltrexone and placebo 
groups. For more details on demographics, see Table 1. 
Table 1. Demographics and drug use histories of patients included in Study III. Continuous variables are presented as 
mean ± standard deviation. 
 Naltrexone (n=20) Placebo (n=20) 
Age (years) 43 ± 10 45 ± 10 
Years of amphetamine use 16 ± 9 21 ± 10 
Days of amphetamine use 
during last month 21 ± 10 23 ± 11 
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Chronic viral hepatitis 75% 70% 
HIV 10% 0% 
Nicotine dependence 80% 90% 
Living alone 95% 75% 
Years in school 11 ± 2  11 ± 4 
Months incarcerated 48 ± 81 58 ± 102 
 
All 40 patients were randomized, but some were not able to perform the fMRI examination 
because of suspected adverse reactions to the medication (n=3; two in the naltrexone and one 
in the placebo group), claustrophobia (n=1) or technical problems (n=3). One patient was lost 
to follow-up for unclear reasons and never took part in the fMRI examination: after 
randomization and having ingested the study medication at the research clinic, he disappeared 
during the un-supervised 50 m walk from the clinic to the MR center. In total, 32 patients 
contributed data for analysis. No serious adverse events occurred during the study. 
The participants’ craving ratings were consistently higher after the drug-related as compared 
to the neutral film clips (mean scores of 68 ± 31 vs. 16 ± 24, p<0.001), which confirms that 
the films worked as intended and that the participants were paying attention. However, the 
carving ratings did not differ between the naltrexone and placebo groups (p>0.1). 
For the fMRI analysis, three participants were excluded from the analysis due to excessive 
head movements during the examination, quantified as >25% of the image volumes above a 
cut-off of 0.3 FD (see above under Methods, section 4.3). This meant that 29 patients had 
complete imaging data of sufficient quality to be included in the analysis. 
Comparing the BOLD activity when viewing drug-related as compared to neutral scenes, we 
found statistically significant activations in the occipital, parietal and temporal cortices, the 
striatum, and cingular cortex (Figure 13 and Table 2). There were no statistically significant 
differences between the naltrexone and placebo groups in the cue-induced BOLD activity of 
our regions of interest. The same results were found in the whole-brain analysis. 
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Figure 13. Drug movie > Neutral movie BOLD activations for the whole sample, regardless of treatment condition 
(n=29). Whole-brain results, p<0.05, with Family-Wise Error correction for multiple comparisons. 
 
Table 2. Coordinates and Z-values for the Drug movie > Neutral movie activations. 
Anatomical region Cluster 
size 
X Y Z Peak Z-
value 
Middle Occipital Gyrus (R)  4834 32 -82 12 7.36 
Inferior Temporal Gyrus 
(R) 
 46 -50 -10 7.15 
Inferior Temporal Gyrus 
(R) 
 44 -66 -8 6.76 
Inferior Occipital Lobule 
(L) 
8712 -48 -72 -4 7.35 
Inferior Occipital Lobule 
(L) 
 -46 -64 -14 7.11 
Inferior Temporal Gyrus 
(L) 
 -46 -48 -18 6.88 
Superior Parietal Lobule 
(R)  
695 26 -64 54 5.84 
Angular Gyrus (R)  28 -64 44 5.70 
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Superior Parietal Lobule 
(R)  
 36 -52 62 5.29 
Fusiform Gyrus (R) 101 38 -34 -28 5.25 
Precentral Lobule (L) 85 -46 2 32 5.08 
Precentral Lobule (L)  -46 6 20 4.96 
Middle Orbitofrontal 
Lobule (L) 
12 -22 38 -18 5.06 
Rolandic Operculum (L) 8 -40 -2 16 4.98 
Superior Frontal Lobule (L) 31 -22 0 56 4.97 
Middle Cingulum (L) 6 -6 -24 42 4.80 
Middle Frontal Gyrus (L) 9 -46 40 18 4.77 
 
In secondary analyses conducted post-hoc, we looked at two well-known moderators of cue 
reactivity. In earlier reviews of the literature, both the length of addiction history and the 
amount of recent drug use has been linked to increased cue reactivity in addiction (108). 
When added as a co-variate in the model, the number of amphetamine-use days in the last 
month did not correlate with neural cue reactivity in our sample. On the other hand, years of 
drug use showed a positive correlation with cue-induced activation of a large cluster in the 
left dorsolateral prefrontal cortex (DLPFC), a finding that remained statistically significant at 
the cluster level after FWE correction (Figure 14). 
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Figure 14. Clusters with cue-induced BOLD activations correlating with years of drug use. Results for the whole 
sample (n=29) with significance level set at p<0.05, with Family-Wise Error correction for multiple comparisons.  
5.4 STUDY IV 
The patients included in this experiment were the same as in Study III, and their background 
has been described above in section 5.3. Here, we also had a control group of healthy 
participants, who were all male and 40 ± 8 years old (not significantly different from the 
patients). There were no significant differences in baseline variables between the naltrexone 
and placebo groups in either the patients or the healthy participants. 
As described above, all 40 patients were randomized, but nine of them were unable to 
successfully perform this experiment in the MR scanner due to suspected adverse reactions to 
the medication, claustrophobia or technical problems. In the group of healthy subjects, three 
persons could not perform the examination because of technical problems and one interrupted 
the examination because of claustrophobia. In total, 31 patients and 26 controls contributed 
data. Head movements were common, particularly in the patient group, and our strict 
threshold for head movements meant that fMRI data from seven patients and one of the 
controls were discarded, leaving 24 patients and 25 healthy subjects with complete data and 
no major movement artifacts. 
In our primary contrast of Active with immediate mask > Neutral with immediate mask, no 
statistically significant activations were found in our predefined regions of interest. Neither 
was any significant activation found when extending the analysis to the whole brain. There 
were no differences between patients and healthy controls and we found no evidence of any 
effect of naltrexone vs. placebo on these measures, although the sample size may have been 
too small to reach adequate power for such a comparison. The secondary analysis of Active 
with delayed mask > Neutral with delayed mask did not reveal any significant activations 
either. 
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6 DISCUSSION 
6.1 ROLE OF THE OPIOID SYSTEM IN THE ACUTE EFFECTS OF 
AMPHETAMINE 
In Study I, contrary to our hypothesis, we did not find any evidence for endogenous opioid 
release in the brain of healthy participants within an hour after an intravenous amphetamine 
injection of 0.3 mg/kg bodyweight. While we were preparing the manuscript for this study, a 
research group at University College London published a paper addressing a similar research 
question, also with the use of 11C-carfentanil PET in healthy volunteers (153). In that study, 
they did find significantly lower 11C-carfentanil BPND after amphetamine intake compared to 
the control condition. Two years later, the same research group published a replication study 
with the same protocol, obtaining similar results as the first one in a new cohort of 
participants (154). 
These seemingly conflicting results can probably be explained by differences in the 
experimental procedures. The two studies from London used oral amphetamine dosing of 0.5 
mg/kg bodyweight, as opposed to our intravenous injections. Oral amphetamine has a slower, 
delayed uptake and also quite different behavioral effects, with much less euphoria than after 
intravenous intake (27). Indeed, the participants in the studies with oral amphetamine did not 
experience any significant euphoria at all, while our participants consistently reported quite 
intense euphoria. However, the most important difference between the studies was probably 
the timing of the PET examinations: instead of starting the examination after a few minutes as 
in our study, they started three hours after the drug intake. This interval is needed for orally 
administered dexamphetamine to reach peak plasma concentrations, but it also leaves more 
time for secondary neurochemical effects to occur (155). Although the exact mechanisms 
behind amphetamine-induced opioid release remain obscure, an interval of more than one 
hour after amphetamine intake seems to be needed in order for any opioid release to be 
measurable with 11C-carfentanil PET in healthy humans. 
The fact that amphetamine-induced opioid release is only measurable after an interval of 
more than one hour contrasts with the timing of the subjective effects of amphetamine, that 
are felt strongly within minutes of an intravenous injection. Unfortunately, the limited 
temporal resolution of PET does not allow for any precise detection of exactly when the 
opioid release occurs. Therefore, it is hard to say to what extent these findings explain why 
naltrexone attenuates the subjective effects of amphetamine, an effect that is apparent within 
the first hour after amphetamine intake, although it is even more evident 2-3 hours after an 
oral dose (68,69). 
In Study II, we examined another hypothesis regarding the mechanism of naltrexone, namely 
that it would attenuate the DA release caused by amphetamine intake. When testing this in 
drug-naïve humans and rats, we found no evidence for such an effect. However, in rats 
previously exposed to amphetamine, naltrexone did attenuate the amphetamine-induced DA 
increase, as recorded with in vivo microdialysis. While not yet experimentally confirmed in 
humans, this finding opens up for a number of different questions regarding the role of DA 
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and opioid interactions in the long-term pathophysiology of addiction, as opposed to the acute 
drug effects at the time of first exposure. 
Of course, this does not answer the question why naltrexone attenuates the subjective 
response to amphetamine in drug-naïve subjects, not only in experienced amphetamine users. 
When examining the results of earlier studies in patients and healthy volunteers, there seems 
to be a trend towards a stronger effect of naltrexone in the patient studies, although this has 
not been formally tested (68,69). Such a difference would be expected given the results 
above, but it remains to be systematically investigated. 
To summarize, amphetamine has acute effects on brain monoamine systems, in particular 
DA, but also induces a release of endogenous opioids in the brain of healthy humans. The 
latter mechanism might help explain why the opioid antagonist naltrexone attenuates the 
subjective effects of amphetamine, but a remaining question is why the opioid release has 
only been observed three hours after the drug intake, while the subjective effects are apparent 
within minutes after an amphetamine injection. Since DA release can be detected very soon 
after amphetamine intake, its timing fits better with the subjective effects of the drug. The 
level of DA release has also been shown to correlate with some of the subjective effects of 
amphetamine (see above, section 2.2), and one hypothesis is that naltrexone exerts its effects 
by interfering with amphetamine-induced DA release. However, we did not find any 
evidence that naltrexone affects amphetamine-induced DA release in healthy humans or 
drug-naïve rats, although in rats chronically exposed to amphetamine, naltrexone actually did 
attenuate the DA release. This might help explain some of the clinical effects of naltrexone in 
amphetamine dependent patients, but how it attenuates the subjective response to 
amphetamine in healthy subjects is still somewhat unclear. Most probably, it involves 
antagonizing the effects of endogenous opioids released after amphetamine intake, but it 
remains to be investigated to what extent this occurs within the time frame relevant for the 
acute subjective effects of amphetamine. 
6.2 ROLE OF THE OPIOID SYSTEM IN CRAVING AND RELAPSE 
While the mechanisms behind the acute effects of addictive drugs are important to study, a 
more pressing clinical dilemma is how to help patients resist craving and avoid relapse in 
amphetamine dependence. One way of doing so could be to reduce the rewarding effects of 
the drug, thereby attenuating the positive reinforcement that may increase the risk of relapse. 
As we have seen above, naltrexone does seem to have such an effect on amphetamine, and it 
might be part of the explanation for its suggested clinical efficacy. 
However, most contemporary theories of addiction emphasize the role of craving and 
negative reinforcement, rather than positive reinforcement, in the later stages of the disease 
(156,157). Clinically, it is also obvious that most long-term amphetamine users do not take 
amphetamine to get a euphoric “high” every day, but rather to be able to get out of bed, to 
feel and function “like normal people”. Simply attenuating the effects of the drug that make 
them feel slightly better for a while might not be a very successful approach, and it would 
require hard work motivating the patient to comply with such a treatment. This is why it is 
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important to understand the mechanisms of craving and develop treatments targeting this 
phenomenon. 
As already discussed in the second chapter of this thesis, some progress has recently been 
made in this field with the help of neuroimaging techniques that allow us to study the human 
brain at work, for instance when exposed to drug-related stimuli that may induce craving. 
Such a cue reactivity paradigm was employed in Study III, which was designed as a 
randomized controlled study, testing whether naltrexone affected cue reactivity in patients 
with severe amphetamine dependence. The rationale for the study was based on earlier 
findings that naltrexone attenuates cue reactivity in alcohol dependent patients (117,118) and 
may prolong the time to relapse in amphetamine dependence (77), a finding that of course 
cannot be explained merely by naltrexone attenuating the acute effects of amphetamine. We 
hypothesized that naltrexone would attenuate cue reactivity as measured with subjective 
craving ratings and BOLD fMRI activity. We did not find evidence in favor of this 
hypothesis, although unfortunately a number of patients were not able to perform the 
experiment or had to be excluded due to movement artifacts, resulting in a somewhat 
underpowered final sample for the analysis of naltrexone vs. placebo. 
While Study III was still ongoing, a research group from University of California, Los 
Angeles (UCLA) published an fMRI study of the effects of naltrexone on cue reactivity in 
methamphetamine users (110). Their sample had less severe addiction than our patients, and 
the cue exposure paradigm employed was also different, but there was still considerable 
overlap with the neural patterns of cue reactivity found in our study. The UCLA study had a 
smaller sample but used repeated measurements of cue reactivity in a cross-over randomized 
study design, allowing for within-subject comparisons of naltrexone vs. placebo. With this 
design, and minimal data loss due to movement artifacts, they were able to find statistically 
significant differences between the naltrexone and placebo conditions in cue reactivity in 
primary sensory-motor areas. This finding is hard to interpret and of unclear relevance, since 
these regions are rarely activated in studies of cue-induced craving and are not typically 
considered parts of the brains motivational systems (95,156). In line with our results, they 
found no difference between the conditions on subjective ratings of craving. 
In other words, there is very limited evidence regarding the possible role of the opioid system 
in craving reactions and relapse in amphetamine dependence. However, some hypotheses 
might be based on findings from other addictive disorders. In this context, the work on 
cocaine dependence using 11C-carfentanil PET, as reviewed above in section 2.4, is of 
particular interest, since the increased opioid receptor binding found in cocaine dependent 
patients has been correlated both with craving and risk of relapse (60,61). This suggested 
pathophysiological mechanism has not yet been studied in amphetamine users, but could of 
course be relevant when trying to explain the mechanism of action of naltrexone. One could 
also speculate that the variability in 11C-carfentanil BPND observed in the patient samples of 
these studies might correlate with individual differences in the response to naltrexone. A 
recent study combining PET and a randomized clinical trial with alcohol dependent patients 
found that a lower striatal 11C-carfentanil BPND was associated with a higher risk of relapse, 
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an effect that seemed to be more pronounced in the naltrexone group, although the study was 
not powered to detect any significant interaction with treatment allocation (158). In the same 
paper, the authors also investigated a sample of alcohol patients post mortem using 
autoradiography with the µ opioid receptor ligand 3H-DAMGO and found a reduced binding 
as compared to controls. This suggests that the increased 11C-carfentanil BPND found in 
earlier studies of recently abstinent alcohol patients reflects reduced levels of competing 
endogenous opioids, rather than increased µ opioid receptor densities (159).  
 
Figure 15. Model of the dynamic changes of the opioid system during the course of alcohol dependence. BPND refers to 
the binding potential for 11C-carfentanil, which is determined by the density of µ opioid receptors and the 
concentration of endogenous opioids, as indicated by the black arrows.  From Hermann et al. 2017 (ref. 158). 
The authors propose a model where both µ opioid receptors and endogenous opioids undergo 
dynamic changes during the cycle of addiction, such that the receptors are continuously 
downregulated during chronic drinking as a reaction to the alcohol-induced endogenous 
opioid activation, forming an allostatic equilibrium (Figure 15). In early withdrawal, the 
endogenous opioid levels drop quickly, contributing to anhedonia and other symptoms (158). 
With prolonged abstinence, the opioid system slowly recovers towards normal function. 
While this model is proposed specifically for alcohol, it might be relevant also for other 
forms of addiction, including stimulant dependence. Indeed, PET studies in recently abstinent 
cocaine patients have consistently found elevated 11C-carfentanil BPND (58,59), while a post 
mortem autoradiography study of cocaine users found reduced 125I-DAMGE binding as 
compared to controls (160), in other words the same pattern as in alcohol patients. At present, 
no relevant studies have investigated these phenomena in amphetamine dependent patients. 
How these proposed dynamic changes during the addiction cycle may affect the impact of 
pharmacological treatments acting on the opioid system is also an important topic for further 
study. 
Another factor that has not yet been sufficiently investigated in amphetamine dependent 
patients is the role of genetic variants, for instance the Asn40Asp (A118G, rs1799971) single 
nucleotide polymorphism of the µ opioid receptor that has been shown to correlate with the 
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therapeutic response to naltrexone in alcohol dependence (53). A limiting factor is the large 
number of patients that need to be tested prospectively in order to get adequate statistical 
power for such comparisons, considering that the 118G variant only has a prevalence of 
about 20% in people with European ancestry. The only study on this topic published so far, 
an open-label study of methamphetamine dependent patients treated with depot-naltrexone, 
only included 11 patients in each group and was therefore underpowered to detect relevant 
differences (161). 
An alternative approach could be to study the effects of Asn40Asp on the response to 
amphetamine and naltrexone in healthy volunteers. However, a recent study did not find any 
evidence that this variant affected amphetamine-induced euphoria (162). It is also worth 
keeping in mind that the results of candidate gene studies in psychiatry so far have been quite 
unsuccessful, even when applied to seemingly simple and promising endophenotypes such as 
response to an amphetamine challenge (163). 
Turning to another proposed mechanism involved in craving and relapse, we found no 
evidence of subliminal drug cue reactivity in Study IV, although our patient sample was the 
largest of any study of this kind. This negative result led us to examine the earlier literature in 
more detail (see also section 2.8). All fMRI studies published so far on subliminal cue 
reactivity in addiction have reported significant results, but most studies come from the same 
laboratory and suffer from several of the common methodological problems mentioned above 
(section 2.6). A closer look reveals that the risk of Type I errors (false positives) due to 
multiple comparisons has not been adequately controlled. Despite the small sample sizes and 
very subtle, subliminal effects under study, statistically significant results in different 
directions are reported in all studies. The two most recent papers, published in 2014 
(122,123), are also examples of a specific problem pointed out by Eklund et al. (98), namely 
that a particular software (AFNI) overestimates group level smoothness and also until 2015 
contained a bug, raising the risk of false positives even further. Since both 2014 studies used 
AFNI for their statistical analyses, the results must be interpreted with great caution until 
reanalysed with more stringent methods. At present, there is no convincing evidence for the 
existence of specific subliminal drug cue reactivity in addiction. 
In summary, there is not yet enough evidence to describe in any detail how the opioid system 
might be involved in craving reactions and relapse in amphetamine dependence. Some 
clinical trials suggest that the opioid antagonist naltrexone reduces the risk of relapse, but the 
exact mechanisms behind this possible effect are not yet known. Two fMRI studies have 
investigated the effect of naltrexone on cue reactivity, but none of them found any effect of 
naltrexone on subjective ratings of craving and the effects on neural cue reactivity are still 
unclear. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
In short, the studies included in this thesis have come to the following conclusions: 
• In Study I, we found no evidence of amphetamine-induced opioid release in healthy 
volunteers, during the first hour after an amphetamine injection. Other studies using 
the same technique have found signs of opioid release three hours after an oral 
amphetamine dose, which suggests that naltrexone attenuates the effects of 
amphetamine at least in part by blocking the effects of endogenous opioids released 
by amphetamine intake. 
• In Study II, naltrexone pre-treatment was found to attenuate amphetamine-induced 
dopamine release in rats with a previous history of chronic amphetamine exposure, an 
effect was not seen in drug-naïve rats or humans. That an opioid antagonist like 
naltrexone has different effects depending on the level of prior amphetamine exposure 
might indicate that the opioid system is involved in the long-term changes in brain 
motivational systems that form part of the disease of addiction.   
• Study III found that patients with severe amphetamine dependence exhibited strong 
cue reactivity, in terms of subjective craving and wide-spread neural activations in 
response to drug-related film clips. However, there was no indictation that naltrexone 
modulates this response and it is unclear whether the opioid system plays any 
significant role in cue-induced craving reactions in amphetamine dependence.  
• Study IV found no evidence for subliminal cue reactivity in a sample of patients with 
severe amphetamine dependence and healthy controls. A closer investigation of 
earlier studies revealed that the evidence for this proposed phenomenon is not 
convincing. 
Karl Popper noted that “every solution of a problem raises new unsolved problems (…) The 
more we learn about the world, and the deeper our learning, the more conscious, specific and 
articulate will be our knowledge of what we do not know, our knowledge of our ignorance” 
(164). While this thesis work has reached few clear solutions, it has hopefully contributed a 
little bit to our knowledge of our ignorance. The work has taken a number of years, and 
during this time the field of addiction neuroimaging has also evolved, with a steadily 
increasing number of studies getting published each month. It could therefore be worthwhile 
to end this thesis by discussing some of the most important developments and challenges 
ahead. 
Neuroimaging is a field of rapid technical development. For PET, new radioligands are being 
synthesized, allowing for new research questions to be addressed. In relation to the subject of 
this thesis, it is particularly interesting to follow the development of specific κ-opioid receptor 
radioligands, which have recently been validated in humans (165). This could make it 
possible to disentangle the roles of different parts of the opioid system in physiological and 
pathological processes in humans. It may also have clinical implications, since κ-opioid 
antagonists are currently being investigated in clinical trials for psychiatric conditions 
including addiction (166).  
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Besides the synthesis of new radioligands, new PET systems and improved methods of 
analysis will probably allow better spatial resolution and more precise measurements in the 
future. 
In fMRI, new cameras with higher magnetic field strengths will improve the signal-to-noise-
ratio. In terms of improving paradigms for the study of cue reactivity, personalized cues are 
likely to be more powerful (167) and the cues might also be presented in a more effective 
way by using virtual reality techniques. With more efficient noise reduction, the current 
standard of visual stimuli could be complemented with good quality audio and perhaps even 
tactile and olfactory stimuli, in order to make the paradigms more realistic and powerful. 
Another promising approach is the use of several imaging modalities in parallel, where the 
strengths of each method contribute to a fuller understanding of the phenomenon under study: 
techniques that could complement PET and fMRI include autoradiography for detailed 
molecular analysis and electroencephalography or magnetoencephalography for superior 
temporal resolution (168). New MR techniques not relying on BOLD may also contribute 
important information, like arterial spin labeling for the measurement of cerebral blood flow 
and diffusion tensor imaging for mapping white matter structure, which can be highly 
relevant in the study of neural networks (169). 
Brain stimulation methods like transcranial magnetic stimulation and deep brain stimulation 
allow for the modulation of neural activity in specific brain regions. In recent years, there has 
been a rapid development of these techniques and a growing number of clinical trials are 
investigating their therapeutic potential in brain disorders, including addiction (170). 
Knowledge gained from imaging studies on the neurocircuitry involved in processes like 
craving could be important in designing efficient brain stimulation treatment protocols. Brain 
stimulation methods might also be highly useful as experimental tools, since they allow the 
neural processes under study to be manipulated rather than just observed (171). Until 
recently, the limited anatomical range of transcranial magnetic stimulation and the risks 
associated with the surgical implant of electrodes for deep brain stimulation have precluded 
their wider use in addiction research. However, the recent development of magnetic coils that 
allow for transcranial stimulation of subcortical structures (172), as well as temporal 
interference techniques for non-invasive deep brain stimulation, although so far only 
validated in rodents (173), might overcome these problems and open up interesting 
experimental possibilities. 
At the same time, crucial improvements could be made in the application of techniques 
already in use, with more efficient paradigms in larger samples, and analysis of data with 
validated statistical methods. The formation of international consortia for collection of 
samples with adequate power has been successful in genetics, and similar projects such as 
ENIGMA are now starting up in the field of psychiatric neuroimaging (174). Study designs 
with control for hereditary factors and/or information on genotype will probably become 
standard, considering the great influence of genetic factors on brain structure and function 
(175). 
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The methodological standards in addiction neuroimaging are far higher today than 15 years 
ago, when some of the first fMRI studies of addiction were published. Hopefully, the next 15 
years will see an even more impressive development. There are however some fundamental 
problems that will need to be addressed before these methods can reach their full potential. 
As mentioned earlier in this thesis, the field of addiction neuroimaging suffers from 
publication bias and other practices that give rise to inflated rates of positive findings in the 
literature (176). Some obvious examples are discussed in Study IV, where all of the earlier 
published studies on the topic might constitute false positives. The same issues seem to be 
prevalent in many other areas of psychological and medical research (177). There are 
probably no simple solutions to these problems, since they are imbedded in the publication 
practices and incentive structures that have dominated medical research for decades. 
However, in terms of a general direction forward, there are strong arguments for a more open 
science: for instance, widespread implementation of study preregistration and sharing of data 
and analytic code are simple measures that could dramatically improve the reliability of the 
published literature (178). While all these measures were not implemented in this thesis 
project from the start, we have taken some steps towards a more open scientific practice 
along the way. Considering the present state of the field, the fact that we have published a 
number of "negative findings" could actually be something to be proud of. We also aim to 
contribute and share data for future patient-level meta-analyses. 
Returning to the topic of naltrexone, there is a need for more high-quality randomized clinical 
trials in order to strengthen the evidence for (or against) the efficacy of naltrexone as a 
treatment for amphetamine dependence. While one study found a significantly prolonged 
time to relapse (77), not all trials have reported this outcome and data on this has not been 
made available upon request (personal communication, 2017). It is also possible that 
naltrexone treatment is beneficial only for a subgroup of amphetamine dependent patients, for 
instance those with more severe addiction. New clinical trials are needed to settle these and 
other questions. Future trials might also consider the inclusion of laboratory sessions or 
neuroimaging procedures to investigate the mechanisms behind the proposed therapeutic 
effects of naltrexone. Hopefully the results of this thesis work can help inform the design of 
such studies and thereby play some part in the further growth of knowledge in this field. 
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8 SVENSKSPRÅKIG SAMMANFATTNING 
Amfetaminberoende ger upphov till en rad medicinska och sociala problem och inte minst i 
de nordiska länderna är det relativt vanligt. Trots detta finns endast begränsad evidens för 
någon specifik behandling som skulle kunna hjälpa patienter att minska risken för återfall. En 
av de mest lovande behandlingsmetoderna för amfetaminberoende är naltrexon, ett läkemedel 
som hämmar aktiviteten i hjärnans opioidsystem. Tidigare studier har visat att naltrexon 
dämpar de subjektiva effekterna av amfetaminintag och vissa kliniska prövningar tyder på att 
det kan minska risken för återfall i amfetaminberoende. Denna avhandling syftade till att med 
hjälp av hjärnavbildning undersöka på vilket sätt naltrexon utövar dessa effekter, för att ge 
bättre förståelse för de neurobiologiska mekanismer som är involverade och underlätta 
fortsatt behandlingsutveckling. 
I Studie I undersökte vi om en amfetamininjektion ger upphov till frisättning av kroppsegna 
opioider i hjärnan. I så fall skulle det kunna förklara varför ett opioidblockerande läkemedel 
som naltrexon dämpar amfetamins effekter. Med hjälp av positronemissionstomografi (PET) 
fann vi dock inga tecken till att amfetamin gav upphov till någon sådan opioidfrisättning hos 
friska försökspersoner utan tidigare erfarenhet av amfetamin. 
I Studie II undersöktes hur förbehandling med naltrexon påverkar den dopaminfrisättning 
som sker i hjärnan efter amfetaminintag, som i vissa tidigare studier visat sig korrelera med 
subjektiva effekter av amfetamin. Om naltrexon dämpar dopaminfrisättningen skulle det 
därför kunna vara en mekanism som förklarar dess dämpning av de subjektiva effekterna. I 
en första delstudie använde vi PET och fann inga tecken till att naltrexon skulle påverka 
dopaminsvaret på amfetaminintag. För att kunna undersöka detta närmre och ge upprepade 
amfetamindoser, gick vi vidare med experiment på råttor, där vi mätte dopaminfrisättning 
med hjälp av mikrodialys. När vi gav råttor en enstaka dos amfetamin påverkade inte 
naltrexon dess effekter, men hos råttor som redan behandlats under längre tid med amfetamin 
fann vi att förbehandling med naltrexon halverade dopaminfrisättningen efter förnyat 
amfetaminintag. 
Studie III syftade till att undersöka hur naltrexon påverkar en annan fas i beroendetillståndet, 
nämligen det drogsug som inte sällan tycks föregå återfall vid beroendetillstånd. Till denna 
studie rekryterade vi 40 amfetaminberoende män, som erhöll naltrexon eller placebo och 
därefter genomgick en undersökning med funktionell magnetresonanstomografi (fMRI). 
Under själva fMRI-undersökningen fick deltagarna se ett antal filmklipp, där vissa hade ett 
drogrelaterat innehåll. Hypotesen var att de drogrelaterade filmerna skulle väcka ett drogsug 
hos patienterna och ge ökad aktivitet i motivationsrelaterade områden i deras hjärnor, samt att 
naltrexon skulle dämpa denna reaktivitet. Vi fann att filmerna gav ett starkt drogsug och även 
påtagligt ökad hjärnaktivitet i vissa hjärnregioner, men vi såg inga signifikanta effekter av 
naltrexon jämfört med placebo. 
Studie IV gick ut på att undersöka hur amfetaminberoende patienter reagerar på drog-
relaterade bilder som presenteras väldigt snabbt och på ett sådant sätt att de inte ens blir 
medvetet varseblivna. Vissa tidigare fMRI-studier har nämligen tyckt sig se att 
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beroendepatienters hjärnor kan reagera även på sådana mycket svaga drogrelaterade stimuli. I 
vår studie fann vi dock inga belägg för att de amfetaminberoende patienterna skulle reagera 
annorlunda på drogrelaterade bilder jämfört med neutrala. Vid en närmare granskning av de 
tidigare studierna fann vi också att deras statistiska metodik var bristfällig, och slutsatsen blir 
att det för närvarande saknas belägg för att beroendepatienters hjärnor reagerar specifikt på 
drogrelaterade stimuli som är så svaga att de inte når medvetandet. 
Sammanfattningsvis har studierna i denna avhandling inte kunnat bekräfta de hypoteser vi 
hade från början avseende mekanismerna bakom naltrexons effekter vid amfetaminberoende. 
Däremot har resultaten gett upphov till nya hypoteser, bland annat om hur samspelet mellan 
hjärnans dopamin- och opioidsystem förändras vid långvarig amfetaminanvändning. De har 
också aktualiserat metodologiska frågor som förhoppningsvis kan bidra till förbättrade 
hjärnavbildningsstudier i framtida beroendeforskning. 
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